

DAFTAR PUSTAKA

- Abu-Halima, M., Keller, A., Becker, L. S., Fischer, U., Engel, A., Ludwig, N., Kern, F., Rounge, T., Langseth, H., Meese, E., & Keller, V. (2023). Dynamic and static circulating cancer microRNA biomarkers – a validation study. *RNA Biology*, 20(1), 1-9. DOI: <https://doi.org/10.1080/15476286.2022.2154470>
- Afshar, S., Najafi, R., Sedighi Pashaki, A., Sharifi, M., Nikzad, S., Gholami, M. H., khoshghadam, A., Amini, R., Karimi, J., & Saidijam, M. (2018). MiR-185 enhances radiosensitivity of colorectal cancer cells by targeting IGF1R and IGF2. *Biomedicine and Pharmacotherapy*, 106, 763–769. DOI: <https://doi.org/10.1016/j.biopha.2018.07.002>
- Ahmed, A. A., Farooqi, M. S., Habeebu, S. S., Gonzalez, E., Flatt, T. G., Wilson, A. L., & Barr, F. G. (2022). NanoString digital molecular profiling of protein and microRNA in rhabdomyosarcoma. *Cancers*, 14(3), 522. DOI: <https://doi.org/10.3390/cancers14030522>
- Akers, J. C., Gonda, D., Kim, R., Carter, B. S., & Chen, C. C. (2013). Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. *Journal of Neuro-Oncology*, 113(1), 1–11. DOI: <https://doi.org/10.1007/s11060-013-1084-8>
- Alfaro-Arnedo, E., López, I. P., Piñeiro-Hermida, S., Canalejo, M., Gotera, C., Sola, J. J., Roncero, A., Peces-Barba, G., Ruíz-Martínez, C., & Pichel, J. G. (2022). IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. *Oncogene*, 41(28), 3625–3639. DOI: <https://doi.org/10.1038/s41388-022-02376-w>
- Alhebshi, H., Tian, K., Patnaik, L., Taylor, R., Bezecny, P., Hall, C., Muller, P. A. J., Safari, N., Creamer, D. P. M., Demonacos, C., Mutti, L., Bittar, M. N., & Krstic-demonacos, M. (2021). Evaluation of the role of p53 tumour suppressor post-translational modifications and ttc5cofactor in lung cancer. *International Journal of Molecular Sciences*, 22(24), 13198. DOI: <https://doi.org/10.3390/ijms222413198>
- Ali, S., Dubaybo, H., & Brand, R. E. (2015). Differential expression of microRNA in tissues and plasma co-exists as a biomarker for pancreatic cancer. *Journal of Cancer Science & Therapy*, 7(11), 336-346. DOI: <https://doi.org/10.4172/1948-5956.1000372>
- Ameis, D., Khoshgoo, N., Iwasiow, B. M., Snarr, P., & Keijzer, R. (2017). MicroRNAs in lung development and disease. *Paediatric Respiratory Reviews*, 22, 38–43. DOI: <https://doi.org/10.1016/j.prrv.2016.12.002>
- Anderson, B., Vue, M., Gayluak, N., Brown, S. J., Bemis, L. T., & Simmons, G. E. (2021). Targeting HMGB1 in the treatment of non-small cell lung adenocarcinoma. *Oncology*, 1(1), 25–37. DOI: <https://doi.org/10.3390/onco1010004>
- Ang, L., Chan, C. P. Y., Yau, W. P., & Seow, W. J. (2020). Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis. *Lung Cancer*, 148, 129–137. DOI: <https://doi.org/10.1016/j.lungcan.2020.08.012>

- Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020). MicroRNAs biogenesis, functions and role in tumor angiogenesis. *Frontiers in Oncology*, 10. DOI: <https://doi.org/10.3389/fonc.2020.581007>
- Ansari, J., Shackelford, R. E., & El-Osta, H. (2016). Epigenetics in non-small cell lung cancer: From basics to therapeutics. *Translational Lung Cancer Research*, 5(2), 155–171. DOI: <https://doi.org/10.21037/tlcr.2016.02.02>
- Archer, J. M., Truong, M. T., Shroff, G. S., Godoy, M. C. B., & Marom, E. M. (2022). Imaging of lung cancer staging. *Seminars in Respiratory and Critical Care Medicine*, 43(6), 862–873. DOI: <https://doi.org/10.1055/s-0042-1753476>
- Babaei, K., Shams, S., Keymoradzadeh, A., Vahidi, S., Hamami, P., Khaksar, R., Norollahi, S. E., & Samadani, A. A. (2020). An insight of microRNAs performance in carcinogenesis and tumorigenesis: an overview of cancer therapy. *Life Sciences*, 240. DOI: <https://doi.org/10.1016/j.lfs.2019.117077>
- Bajo-Santos, C., Brokāne, A., Zayakin, P., Endzeliņš, E., Soboļevska, K., Belovs, A., Jansons, J., Sperga, M., Llorente, A., Radoviča-Spalviņa, I., Lietuvietis, V., & Linē, A. (2023). Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies. *Frontiers in Molecular Biosciences*, 10. DOI: <https://doi.org/10.3389/fmolb.2023.980433>
- Bafiti, V., Thanou, E., Ouzounis, S., Kotsakis, A., Georgoulas, V., Lianidou, E., Katsila, T., & Markou, A. (2024). Profiling plasma extracellular vesicle metabolites and miRNAs: an unobserved clue for predicting relapse in patients with early-stage NSCLC. *Cancers*, 16(22). DOI: <https://doi.org/10.3390/cancers16223729>
- Bakulski, K. M., Dou, J., Lin, N., London, S. J., & Colacino, J. A. (2019). DNA methylation signature of smoking in lung cancer is enriched for exposure signatures in newborn and adult blood. *Scientific Reports*, 9(1). DOI: <https://doi.org/10.1038/s41598-019-40963-2>
- Balachander, K., Vijayashree Priyadharsini, J., & Paramasivam, A. (2022). Advances in oral cancer early diagnosis and treatment strategies with liquid biopsy-based approaches. *Oral Oncology*, 134, 106108. DOI: <https://doi.org/10.1016/j.oraloncology.2022.106108>
- Balannolla, S., Kousar Nikhath, A., & Yeruva, S. (2022). Detection and classification of lung carcinoma using CT scans. *Journal of Physics: Conference Series*, 2286(1). DOI: <https://doi.org/10.1088/1742-6596/2286/1/012011>
- Banack, S. A., Dunlop, R. A., Stommel, E. W., Mehta, P., & Cox, P. A. (2022). MiRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*, 442(5), 120396. DOI: <https://doi.org/10.1016/j.jns.2022.120396>
- Bao, L., Lv, L., Feng, J., Chen, Y., Wang, X., Han, S., & Zhao, H. (2017). MiR-876-5p suppresses epithelial–mesenchymal transition of lung cancer by directly down-regulating bone morphogenetic protein 4. *Journal of Biosciences*, 42(4), 671–681. DOI: <https://doi.org/10.1007/s12038-017-9722-5>
- Barbieri, M. A., Fernandez-Pol, S., Hunker, C., Horazdovsky, B. H., & Stahl, P. D. (2004). Role of Rab5 in EGF receptor-mediated signal transduction. *Eur. J. Cell Biol.*, 83, 305–315.
- Baroni, S., Romero-Cordoba, S., Plantamura, I., Dugo, M., D'Ippolito, E., Cataldo, A., Cosentino, G., Angeloni, V., Rossini, A., Daidone, M. G., & Iorio, M. V. (2016).

- Exosome-mediated delivery of miR-9 induces cancer-Associated fibroblast-like properties in human breast fibroblasts. *Cell Death and Disease*, 7(7), e2312. DOI: <https://doi.org/10.1038/cddis.2016.224>
- Bata, N., & Cosford, N. D. P. (2021). Cell survival and cell death at the intersection of autophagy and apoptosis: implications for current and future cancer therapeutics. *ACS Pharmacology and Translational Science*, 4(6), 1728–1746. DOI: <https://doi.org/10.1021/acsptsci.1c00130>
- Batra, U., Biswas, B., Prabhash, K., & Krishna, M. V. (2023). Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. *BMJ Open Respiratory Research*, 10(1). DOI: <https://doi.org/10.1136/bmjresp-2022-001492>
- Battistelli, M., & Falcieri, E. (2020). Apoptotic bodies: Particular extracellular vesicles involved in intercellular communication. *Biology*, 9(1). DOI: <https://doi.org/10.3390/biology9010021>
- Batram, A. M., Bachiller, M., & Martín-Antonio, B. (2020). Senescence in the development and response to cancer with immunotherapy: A double-edged sword. *International Journal of Molecular Sciences*, 21(12), 1–31. DOI: <https://doi.org/10.3390/ijms21124346>
- Beadsmoore, C. J., & Screaton, N. J. (2003). *Classification, staging and prognosis of lung cancer*. *European Journal of Radiology*, (45), 8–17. www.elsevier.com/locate/ejrad
- Beasley, M. B., Dembitzer, F. R., & Flores, R. M. (2016). Surgical pathology of early stage non-small cell lung carcinoma. *Annals of Translational Medicine*, 4(12), 1–8. DOI: <https://doi.org/10.21037/atm.2016.06.13>
- Becker, C., Hammerle-Fickinger, A., Riedmaier, I., & Pfaffl, M. W. (2010). mRNA and microRNA quality control for RT-qPCR analysis. *Methods*, 50(4), 237–243. DOI: <https://doi.org/10.1016/j.ymeth.2010.01.010>
- Beit-Yannai, E., Tabak, S., & Stamer, W. D. (2018). Physical exosome: exosome interactions. *Journal of Cellular and Molecular Medicine*, 22(3), 2001–2006. DOI: <https://doi.org/10.1111/jcmm.13479>
- Ben Saad, E., Oroya, A., Anto, N. P., Bachais, M., & Rudd, C. E. (2024). PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity. *Cell Reports*, 43(11). DOI: <https://doi.org/10.1016/j.celrep.2024.114907>
- Bergbower, E. A. S., Pierson, R. N., & Azimzadeh, A. M. (2020). Multi-gene technical assessment of qPCR and NanoString n-Counter analysis platforms in cynomolgus monkey cardiac allograft recipients. *Cellular Immunology*, 347. DOI: <https://doi.org/10.1016/j.cellimm.2019.104019>
- Bi, N., Cao, J., Song, Y., Shen, J., Liu, W., Fan, J., He, J., Shi, Y., Zhang, X., Lu, N., Zhan, Q., & Wang, L. (2014). A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. *Plos One*, 9(3). DOI: <https://doi.org/10.1371/journal.pone.0091388>
- Biton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., Wislez, M., Germain, C., Laurent-Puig, P., Dieu-Nosjean, M. C., Cremer, I., Herbst, R., Blons, H., & Damotte, D. (2018). TP53, STK11, and EGFR mutations predict tumor immune

- profile and the response to anti-PD-1 in lung adenocarcinoma. *Clinical Cancer Research*, 24(22), 5710–5723. DOI: <https://doi.org/10.1158/1078-0432.CCR-18-0163>
- Blondal, T., Jensby Nielsen, S., Baker, A., Andreasen, D., Mouritzen, P., Wrang Teilum, M., & Dahlsveen, I. K. (2013). Assessing sample and miRNA profile quality in serum and plasma or other biofluids. *Methods*, 59(1), S1-S6. DOI: <https://doi.org/10.1016/j.ymeth.2012.09.015>
- Boesch, M., Horvath, L., Baty, F., Pircher, A., Wolf, D., Spahn, S., Straussman, R., Tilg, H., & Brutsche, M. H. (2022). Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. *Journal for immunotherapy of cancer*, 10(11). DOI: <https://doi.org/10.1136/jitc-2022-005401>
- Bonora, M., Missiroli, S., Perrone, M., Fiorica, F., Pinton, P., & Giorgi, C. (2021). Mitochondrial control of genomic instability in cancer. *Cancers*, 13(8). DOI: <https://doi.org/10.3390/cancers13081914>
- Borriello, L., Coste, A., Traub, B., Sharma, V. P., Karagiannis, G. S., Lin, Y., Wang, Y., Ye, X., Duran, C. L., Chen, X., Friedman, M., Sosa, M. S., Sun, D., Dalla, E., Singh, D. K., Oktay, M. H., Aguirre-Ghiso, J. A., Condeelis, J. S., & Entenberg, D. (2022). Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. *Nature Communications*, 13(1). DOI: <https://doi.org/10.1038/s41467-022-28076-3>
- Bosco, B., Rossi, A., Rizzotto, D., Hamadou, M. H., Bisio, A., Giorgetta, S., Perzulli, A., Bonollo, F., Gaucherot, A., Catez, F., Diaz, J. J., Dassi, E., & Inga, A. (2021). DHX30 coordinates cytoplasmic translation and mitochondrial function contributing to cancer cell survival. *Cancers*, 13(17). DOI: <https://doi.org/10.3390/cancers13174412>
- Brambilla, E., & Gazdar, A. (2009). Pathogenesis of lung cancer signalling pathways: roadmap for therapies. *European Respiratory Journal*, 33(6), 1485–1497. DOI: <https://doi.org/10.1183/09031936.00014009>
- Brambilla, E., Travis, W. D., Colby, T. V., Corrin, B., & Shimosato, Y. (2001). The new world health organization classification of lung tumours. *European Respiratory Journal*, 18(6): 1059–1068. DOI: <https://doi.org/10.1183/09031936.01.00275301>
- Brhane, Y., Yang, P., Christiani, D. C., Liu, G., McLaughlin, J. R., Brennan, P., Shete, S., Field, J. K., Tardon, A., Kohno, T., Shiraishi, K., Matsuo, K., Bosse, Y., Amos, C. I., & Hung, R. J. (2020). Genetic determinants of lung cancer prognosis in never smokers: A pooled analysis in the international lung cancer consortium. *Cancer Epidemiology Biomarkers and Prevention*, 29(10), 1983–1992. DOI: <https://doi.org/10.1158/1055-9965.EPI-20-0248>
- Bros, M., Haas, K., Moll, L., & Grabbe, S. (2019). Rhoa as a key regulator of innate and adaptive immunity. *Cells*, 8(7). DOI: <https://doi.org/10.3390/cells8070733>
- Bubendorf, L., Lantuejoul, S., de Langen, A. J., & Thunnissen, E. (2017). Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. *European Respiratory Review*, 26(144). DOI: <https://doi.org/10.1183/16000617.0007-2017>

- Budakoti, M., Panwar, A. S., Molpa, D., Singh, R. K., Büsselberg, D., Mishra, A. P., Coutinho, H. D. M., & Nigam, M. (2021). Micro-RNA: The darkhorse of cancer. *Cellular Signalling*, 83. DOI: <https://doi.org/10.1016/j.cellsig.2021.109995>
- Buermans, H. P. J., Ariyurek, Y., van Ommen, G., den Dunnen, J. T., & 'T Hoen, P. A. C. (2010). New methods for next generation sequencing based microRNA expression profiling. *BMC Genomics*, 11(1). DOI: <https://doi.org/10.1186/1471-2164-11-716>
- Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022). Hypoxia-inducible factor-1: a novel therapeutic target for the management of cancer, drug resistance, and cancer-related pain. *Cancers*, 14(24). DOI: <https://doi.org/10.3390/cancers14246054>
- Bulatowicz, J. J., & Wood, T. L. (2022). Activation versus inhibition of IGF1R: a dual role in breast tumorigenesis. *Frontiers in Endocrinology*, 13. DOI: <https://doi.org/10.3389/fendo.2022.911079>
- Cai, X., Huang, W., Huang, J., Zhu, X., Wang, L., Xia, Z., & Xu, L. (2024). CAPZB mRNA is a novel biomarker for cervical high-grade squamous lesions. *Scientific Reports*, 14(1). DOI: <https://doi.org/10.1038/s41598-024-71112-z>
- Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019). Cellular senescence: aging, cancer, and injury. *Physiol Rev*, 99, 1047–1078. DOI: <https://doi.org/10.1152/physrev.00020.2018.-Cellular>
- Campbell, J. D., Liu, G., Luo, L., Xiao, J., Gerrein, J., Juan-Guardela, B., Tedrow, J., Alekseyev, Y. O., Yang, I. V., Correll, M., Geraci, M., Quackenbush, J., Sciurba, F., Schwartz, D. A., Kaminski, N., Johnson, W. E., Monti, S., Spira, A., Beane, J., & Lenburg, M. E. (2015). Assessment of microRNA differential expression and detection in multiplexed small RNA sequencing data. *RNA*, 21(2), 164–171. DOI: <https://doi.org/10.1261/rna.046060.114>
- Camussi, G., Deregibus, M.-C., Bruno, S., Grange, C., Fonsato, V., & Tetta, C. (2011). Exosome/microvesicle-mediated epigenetic reprogramming of cells. *American Journal of Cancer Research*, 1(1), 98–110.
- Cao, F., Liu, S., Li, Z., Meng, L., Sang, M., & Shan, B. (2022). Activation of circ_0072088/miR-1261/PIK3CA pathway accelerates lung adenocarcinoma progression. *Thoracic Cancer*, 13(11), 1548–1557. DOI: <https://doi.org/10.1111/1759-7714.14369>
- Cargill, K. R., Hasken, W. L., Gay, C. M., & Byers, L. A. (2021). Alternative energy: breaking down the diverse metabolic features of lung cancers. *Frontiers in Oncology*, 11. DOI: <https://doi.org/10.3389/fonc.2021.757323>
- Carneiro, B. A., & El-Deiry, W. S. (2020). Targeting apoptosis in cancer therapy. *Nature Reviews Clinical Oncology*, 17(7), 395–417. DOI: <https://doi.org/10.1038/s41571-020-0341-y>
- Cavalcante, G. C., Schaan, A. P., Cabral, G. F., Santana-Da-Silva, M. N., Pinto, P., Vidal, A. F., & Ribeiro-Dos-Santos, Â. (2019). A cell's fate: an overview of the molecular biology and genetics of apoptosis. *International Journal of Molecular Sciences*, 20(17). DOI: <https://doi.org/10.3390/ijms20174133>
- Chalishazar, M. D., Wait, S. J., Huang, F., Ireland, A. S., Mukhopadhyay, A., Lee, Y., Schuman, S. S., Guthrie, M. R., Berrett, K. C., Vahrenkamp, J. M., Hu, Z., Kudla, M., Modzelewska, K., Wang, G., Ingolia, N. T., Gertz, J., Lum, D. H., Cosulich, S. C., Bomalaski, J. S., ... Oliver, T. G. (2019). MYC-driven small-cell lung cancer is

- metabolically distinct and vulnerable to arginine depletion. *Clinical Cancer Research*, 25(16), 5107–5121. DOI: <https://doi.org/10.1158/1078-0432.CCR-18-4140>
- Chan, E. T., & Kural, C. (2024). Targeting endocytosis to sensitize cancer cells to programmed cell death. *Biochemical Society Transaction*, 52(4), 1703–1713. DOI: <https://doi.org/10.1042/BST20231332>
- Chang, S. H., Minai-Tehrani, A., Shin, J. Y., Park, S., Kim, J. E., Yu, K. N., Hong, S. H., Hong, C. M., Lee, K. H., Beck, G. R., & Cho, M. H. (2012). Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin. *Journal of Radiation Research*, 53(3), 422–432. DOI: <https://doi.org/10.1269/jrr.11148>
- Chaudhry, G. E. S., Md Akim, A., Sung, Y. Y., & Sifzizul, T. M. T. (2022). Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. *Frontiers in Pharmacology*, 13. DOI: <https://doi.org/10.3389/fphar.2022.842376>
- Chaudhuri, A. A. (2023). Cell-free DNA liquid biopsy: the epitome of personalized precision oncology. *Radiation Research*, 200(1), 92–95. DOI: <https://doi.org/10.1667/rade-23-00044.1>
- Chavez-Dominguez, R., Perez-Medina, M., Lopez-Gonzalez, J. S., Galicia-Velasco, M., & Aguilar-Cazares, D. (2020). The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity. *Frontiers in Oncology*, 10. DOI: <https://doi.org/10.3389/fonc.2020.578418>
- Chen, C., Ridzon, D. A., Broomer, A. J., Zhou, Z., Lee, D. H., Nguyen, J. T., Barbisin, M., Xu, N. L., Mahuvakar, V. R., Andersen, M. R., Lao, K. Q., Livak, K. J., & Guegler, K. J. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Research*, 33(20). DOI: <https://doi.org/10.1093/nar/gni178>
- Chen, C., Wen, L., Chen, G., Yang, F., Chen, Z., Ji, J., & Gu, J. (2025). Pan-cancer analysis of ITGB3 as a potential prognostic and immunological biomarker. *Discover Oncology*, 16(1). DOI: <https://doi.org/10.1007/s12672-025-02300-0>
- Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022). Genomic instability, inflammatory signaling and response to cancer immunotherapy. *Biochimica et Biophysica Acta - Reviews on Cancer*, 1877(1). DOI: <https://doi.org/10.1016/j.bbcan.2021.188661>
- Chen, M., & Zhao, H. (2019). Next-generation sequencing in liquid biopsy: cancer screening and early detection. *Human Genomics*, 13(1), 34. DOI: <https://doi.org/10.1186/s40246-019-0220-8>
- Chen, P., Jiang, P., Yu, X., & Yang, M. (2021). Knockdown of microRNA-126 Suppresses Non-Small-Cell Lung Cancer via Inhibiting PI3K-AKT-mTOR Pathway. *Research Square*. DOI: <https://doi.org/10.21203/rs.3.rs-861155/v1>
- Chen, S., Wang, Q., Zhou, X. M., Zhu, J. P., Li, T., & Huang, M. (2016). MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor. *Molecular Medicine Reports*, 14(1), 949–954. DOI: <https://doi.org/10.3892/mmr.2016.5332>
- Chen, Y., Hu, H., Tan, S., Dong, Q., Fan, X., Wang, Y., Zhang, H., & He, J. (2022). The role of neutrophil extracellular traps in cancer progression, metastasis and therapy.

- Experimental Hematology and Oncology*, 11(1). DOI: <https://doi.org/10.1186/s40164-022-00345-3>
- Chen, Y., Tsai, Y. H., & Tseng, S. H. (2016). Regulation of the expression of cytoplasmic polyadenylation element binding proteins for the treatment of cancer. *Anticancer Research*, 36(11), 5673–5680. DOI: <https://doi.org/10.21873/anticancer.11150>
- Cheng, L., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Lopez-Beltran, A., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012). Molecular pathology of lung cancer: Key to personalized medicine. *Modern Pathology*, 25(3), 347–369. DOI: <https://doi.org/10.1038/modpathol.2011.215>
- Cheng, L., & Hill, A. F. (2022). Therapeutically harnessing extracellular vesicles. *Nature Reviews Drug Discovery*, 21(5), 379–399. DOI: <https://doi.org/10.1038/s41573-022-00410-w>
- Chetty, C., Maddirela, D. R., Gogineni, V. R., Chittivelu, S., Rao, J. S., & Moorthy, B. (2014). MicroRNA-874 impedes angiogenesis in non-small cell lung cancer. *Cancer Research*, 74(19), 5219. DOI: <https://doi.org/10.1158/1538-7445.am2014-5219>
- Chilimoniuk, J., Erol, A., Rödiger, S., & Burdukiewicz, M. (2024). Challenges and opportunities in processing NanoString nCounter data. *Computational and Structural Biotechnology Journal*, 23, 1951–1958. DOI: <https://doi.org/10.1016/j.csbj.2024.04.061>
- Choi, H. S., Jeong, B. K., Jeong, H., Lee, Y. H., Ha, I. B., Song, J. H., & Kang, K. M. (2017). Application of the new 8th TNM staging system for non-small cell lung cancer: Treated with curative concurrent chemoradiotherapy. *Radiation Oncology*, 12(1). DOI: <https://doi.org/10.1186/s13014-017-0848-2>
- Cizeron-Clairac, G., Lallemand, F., Vacher, S., Lidereau, R., Bieche, I., & Callens, C. (2015). MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers. *BMC Cancer*, 15(1). DOI: <https://doi.org/10.1186/s12885-015-1505-5>
- Cominetti, M. R., Altei, W. F., & Selistre-De-araujo, H. S. (2019). Metastasis inhibition in breast cancer by targeting cancer cell extravasation. *Breast Cancer: Targets and Therapy*, 11, 165–178. DOI: <https://doi.org/10.2147/BCTT.S166725>
- Connell, P. P., & Weichselbaum, R. R. (2011). A downside to apoptosis in cancer therapy. *Nature Medicine*, 17(7), 780–782. DOI: <https://doi.org/10.1038/nm0711-780>
- Çorbacioğlu, Ş. K., & Aksel, G. (2023). Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value. *Turkish Journal of Emergency Medicine*, 23(4), 195–198. DOI: https://doi.org/10.4103/tjem.tjem_182_23
- Corbetta, S., Gualdoni, S., Ciceri, G., Monari, M., Zuccaro, E., Tybulewicz, V. L. J., & De Curtis, I. (2009). Essential role of Rac1 and Rac3 GTPases in neuronal development. *The FASEB Journal*, 23(5), 1347–1357. DOI: <https://doi.org/10.1096/fj.08-121574>
- Corda, G., & Sala, A. (2017). Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. *Oncogenesis*, 6(7), e364. DOI: <https://doi.org/10.1038/oncsis.2017.69>

- Costa, P. M. da S., Sales, S. L. A., Pinheiro, D. P., Pontes, L. Q., Maranhão, S. S., Pessoa, C. do Ó., Furtado, G. P., & Furtado, C. L. M. (2023). Epigenetic reprogramming in cancer: from diagnosis to treatment. *Frontiers in Cell and Developmental Biology*, 11. DOI: <https://doi.org/10.3389/fcell.2023.1116805>
- Crossland, R. E., Albiero, A., Sanjurjo-Rodríguez, C., Reis, M., Resteu, A., Anderson, A. E., Dickinson, A. M., Pratt, A. G., Birch, M., McCaskie, A. W., Jones, E., & Wang, X. (2023). MicroRNA profiling of low concentration extracellular vesicle RNA utilizing NanoString nCounter technology. *Journal of Extracellular Biology*, 2(1). DOI: <https://doi.org/10.1002/jex2.72>
- Cui, F., Hao, Z. xue, Li, J., Zhang, Y. lei, Li, X. kai, & He, J. xing. (2020). SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p. *Molecular Genetics and Genomic Medicine*, 8(5). DOI: <https://doi.org/10.1002/mgg3.1195>
- Cybulski, C., Masojć, B., Oszutowska, D., Jaworowska, E., Grodzki, T., Waloszczyk, P., Serwatowski, P., Pankowski, J., Huzarski, T., Byrski, T., Górski, B., Jakubowska, A., Dębniak, T., Wokołorczyk, D., Gronwald, J., Tarnowska, C., Serrano-Fernández, P., Lubiński, J., & Narod, S. A. (2008). Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. *Carcinogenesis*, 29(4), 762–765. DOI: <https://doi.org/10.1093/carcin/bgn044>
- Dai, S., Mo, Y., Wang, Y., Xiang, B., Liao, Q., Zhou, M., Li, X., Li, Y., Xiong, W., Li, G., Guo, C., & Zeng, Z. (2020). Chronic stress promotes cancer development. *Frontiers in Oncology*, 10. DOI: <https://doi.org/10.3389/fonc.2020.01492>
- Dai, W., He, J., Zheng, L., Bi, M., Hu, F., Chen, M., Niu, H., Yang, J., Luo, Y., Tang, W., & Sheng, M. (2019). MiR-148b-3p, miR-190b, and miR-429 regulate cell progression and act as potential biomarkers for breast cancer. *Journal of Breast Cancer*, 22(2), 219–236. DOI: <https://doi.org/10.4048/jbc.2019.22.e19>
- Daugaard, I., Venø, M. T., Yan, Y., Kjeldsen, T. E., Lamy, P., Hager, H., Kjems, J., & Hansen, L. L. (2017). Small RNA sequencing reveals metastasis-related microRNAs in lung adenocarcinoma. *Oncotarget*, 8(16), 27047–27061. DOI: <https://doi.org/10.18632/oncotarget.15968>
- Davidson, M. R., Gazdar, A. F., & Clarke, B. E. (2013). The pivotal role of pathology in the management of lung cancer. *Journal of Thoracic Disease*, 5(S5), S463-S478. DOI: <https://doi.org/10.3978/j.issn.2072-1439.2013.08.43>
- De Sousa, V. M. L., & Carvalho, L. (2018). Heterogeneity in lung cancer. *Pathobiology*, 85(2), 96–107. DOI: <https://doi.org/10.1159/000487440>
- de Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. *Cancer Cell*, 41(3), 374–403. DOI: <https://doi.org/10.1016/j.ccell.2023.02.016>
- Değerli, E., Torun, V., & Cansaran-Duman, D. (2020). MiR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2. *Biological Research*, 53(1). DOI: <https://doi.org/10.1186/s40659-020-00285-4>
- Dejima, H., Iinuma, H., Kanaoka, R., Matsutani, N., & Kawamura, M. (2017). Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. *Oncology Letters*, 13(3), 1256–1263. DOI: <https://doi.org/10.3892/ol.2017.5569>

- DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. 44(3).
- Demkow, U. (2021). Neutrophil extracellular traps (NETs) in cancer invasion, evasion and metastasis. *Cancers*, 13 (17). DOI: <https://doi.org/10.3390/cancers13174495>
- Denninghoff, V., Russo, A., de Miguel-Pérez, D., Malapelle, U., Benyounes, A., Gittens, A., Cardona, A. F., & Rolfo, C. (2021). Small cell lung cancer: State of the art of the molecular and genetic landscape and novel perspective. *Cancers*, 13(7). DOI: <https://doi.org/10.3390/cancers13071723>
- Dennis, L., Rhodes, M., & Maclean, K. (2015). Targeted miRNA discovery and validation using the nCounter® platform. www.nanosttring.com
- Deo, S. V. S., Sharma, J., & Kumar, S. (2022). Globocan 2020 report on global cancer burden: challenges and opportunities for surgical oncologists. *Annals of Surgical Oncology*, 29(11), 6497–6500. DOI: <https://doi.org/10.1245/s10434-022-12151-6>
- Deroide, N., Li, X., Lerouet, D., Van Vré, E., Baker, L., Harrison, J., Poittevin, M., Masters, L., Nih, L., Margail, I., Iwakura, Y., Ryffel, B., Pocard, M., Tedgui, A., Kubis, N., & Mallat, Z. (2013). MFG8 inhibits inflammasome-induced IL-1 β production and limits postischemic cerebral injury. *Journal of Clinical Investigation*, 123(3), 1176–1181. DOI: <https://doi.org/10.1172/JCI65167>
- Detterbeck, F. C. (2018). The eighth edition TNM stage classification for lung cancer: What does it mean on main street?. *Journal of Thoracic and Cardiovascular Surgery*, 155(1), 356–359. DOI: <https://doi.org/10.1016/j.jtcvs.2017.08.138>
- Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017). The eighth edition lung cancer stage classification. *Chest*, 151(1), 193–203. DOI: <https://doi.org/10.1016/j.chest.2016.10.010>
- Dietel, M., Bubendorf, L., Dingemans, A. M. C., Doms, C., Elmberger, G., García, R. C., Kerr, K. M., Lim, E., López-Ríos, F., Thunnissen, E., Van Schil, P. E., & Von Laffert, M. (2016). Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the european expert group. *Thorax*, 71(2), 177–184. DOI: <https://doi.org/10.1136/thoraxjnl-2014-206677>
- Dilsiz, N. (2020). Role of exosomes and exosomal microRNAs in cancer. *Future Science OA*, 6(4). DOI: <https://doi.org/10.2144/fsoa-2019-0116>
- Diniz, G., Ünlü, I., & Kömürçüoğlu, B. (2017). Histopathological and molecular features of lung cancer. *The Journal of Tepecik Education and Research Hospital*, 27(2), 77–87. DOI: <https://doi.org/10.5222/terh.2017.077>
- Dong, Z., Gu, W., & Xu, L. (2022). Exploring the mechanism of miR320a in regulating PDL1 upon lung cancer pathogenesis. *Acta Biochimica Polonica*, 69(3), 567–572. DOI: https://doi.org/10.18388/abp.2020_5852
- Donoso-Quezada, J., Ayala-Mar, S., & González-Valdez, J. (2021). The role of lipids in exosome biology and intercellular communication: function, analytics and applications. *Traffic*, 22(7), 204–220. DOI: <https://doi.org/10.1111/tra.12803>
- Doyle, L. M., & Wang, M. Z. (2019). Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. *Cells*, 8(7). DOI: <https://doi.org/10.3390/cells8070727>

- Du, Z., & Lovly, C. M. (2018). Mechanisms of receptor tyrosine kinase activation in cancer. *Molecular Cancer*, 17(1). DOI: <https://doi.org/10.1186/s12943-018-0782-4>
- Duan, X., Xing, Z., Qiao, L., Qin, S., Zhao, X., Gong, Y., & Li, X. (2024). The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. *Frontiers in Immunology*, 15. DOI: <https://doi.org/10.3389/fimmu.2024.1495221>
- Dunlop, R. A., Banack, S. A., & Cox, P. A. (2021). A comparison of the efficiency of RNA extraction from extracellular vesicles using the qiagen rneasy minelute versus enzymax llc RNA tini spin columns and qPCR of miRNA. *Biology Methods and Protocols*, 6(1), 1–9. DOI: <https://doi.org/10.1093/biomethods/bpab015>
- Ercelep, O. (2020). Comparison of seventh and eighth editions of TNM staging classification and evaluation of survivals in operated non-small cell lung carcinomas: single center experience. *Eurasian Journal of Medical Investigation*, 4(2), 243–246. DOI: <https://doi.org/10.14744/ejmi.2020.81008>
- Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., Lovat, F., Fadda, P., Mao, C., Nuovo, G. J., Zanesi, N., Crawford, M., Ozer, G. H., Wernicke, D., Alder, H., Caligiuri, M. A., Nana-Sinkam, P., Perrotti, D., & Croce, C. M. (2012). MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. *Proceedings of the National Academy of Sciences of the United States of America*, 109(31). DOI: <https://doi.org/10.1073/pnas.1209414109>
- Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020). Metabolic reprogramming and cancer progression. *Science*, 368, 6487. DOI: <https://doi.org/10.1126/science.aaw5473>
- Febres-Aldana, C. A., Chang, J. C., Ptashkin, R., Wang, Y., Gedvilaite, E., Baine, M. K., Travis, W. D., Ventura, K., Bodd, F., Yu, H. A., Quintanal-Villalonga, A., Lai, W. V., Egger, J. V., Offin, M., Ladanyi, M., Rudin, C. M., & Rekhtman, N. (2022). Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct rb-proficient subset. *Clinical Cancer Research*, 28(21), 4702–4713. DOI: <https://doi.org/10.1158/1078-0432.CCR-22-1115>
- Fefilova, E., Kirdeeva, Y., Parfenyev, S., Daks, A., Fedorova, O., Sorokina, M., Ha, N. X., Huong, T. T., Loc, V. T., Hai, P. T., Cuong, N. M., Barlev, N., & Shuvalov, O. (2025). MDM2 up-regulates the energy metabolism in NSCLC in a p53-independent manner. *Biochemical and Biophysical Research Communications*, 743. DOI: <https://doi.org/10.1016/j.bbrc.2024.151169>
- Fellizar, A., Refuerzo, V., Ramos, J. D., & Albano, P. M. (2023). Expression of specific microRNAs in tissue and plasma in colorectal cancer. *Journal of Pathology and Translational Medicine*, 57(3), 147–157. DOI: <https://doi.org/10.4132/JPTM.2022.02.19>
- Feng, Y., Liu, X., & Pauklin, S. (2021). 3D chromatin architecture and epigenetic regulation in cancer stem cells. *Protein and Cell*, 12(6), 440–454. DOI: <https://doi.org/10.1007/s13238-020-00819-2>
- Feng, Z., Yuan, L., Ma, L., Yu, W., Kheir, F., Käsmann, L., Brueckl, W. M., Jin, K., Wang, D., Shen, Y., Li, R., & Tian, H. (2024). Peptidyl-prolyl isomerase F as a prognostic biomarker associated with immune infiltrates and mitophagy in lung

- adenocarcinoma. *Translational Lung Cancer Research*, 13(6), 1346–1364. DOI: <https://doi.org/10.21037/tlcr-24-344>
- Ferguson, L. R., Chen, H., Collins, A. R., Connell, M., Damia, G., Dasgupta, S., Malhotra, M., Meeker, A. K., Amedei, A., Amin, A., Ashraf, S. S., Aquilano, K., Azmi, A. S., Bhakta, D., Bilsland, A., Boosani, C. S., Chen, S., Ciriolo, M. R., Fujii, H., ... Maxwell, C. A. (2015). Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. *Seminars in Cancer Biology*, 35, S5–S24. DOI: <https://doi.org/10.1016/j.semcancer.2015.03.005>
- Fong, M. Y., Zhou, W., Liu, L., Alontaga, A. Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S. T. F., Li, S., Chin, A. R., Somlo, G., Palomares, M., Li, Z., Tremblay, J. R., Tsuyada, A., Sun, G., Reid, M. A., Wu, X., Swiderski, P., ... Wang, S. E. (2015). Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. *Nature Cell Biology*, 17(2), 183–194. DOI: <https://doi.org/10.1038/ncb3094>
- Fortunato, O., Borzi, C., Milione, M., Centonze, G., Conte, D., Boeri, M., Verri, C., Moro, M., Facchinetti, F., Andriani, F., Roz, L., Caleca, L., Huber, V., Cova, A., Camisaschi, C., Castelli, C., Cancila, V., Tripodo, C., Pastorino, U., & Sozzi, G. (2019). Circulating miR-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. *International Journal of Cancer*, 144(11), 2746–2761. DOI: <https://doi.org/10.1002/ijc.31988>
- Fortunato, O., Gasparini, P., Boeri, M., & Sozzi, G. (2019). Exo-miRNAs as a new tool for liquid biopsy in lung cancer. *Cancers*, 11(6). DOI: <https://doi.org/10.3390/cancers11060888>
- Foye, C., Yan, I. K., David, W., Shukla, N., Habboush, Y., Chase, L., Ryland, K., Kesari, V., & Patel, T. (2017). Comparison of miRNA quantitation by Nanostring in serum and plasma samples. *PLoS One*, 12(12). DOI: <https://doi.org/10.1371/journal.pone.0189165>
- Frankhouser, D. E., O'meally, D., Branciamore, S., Uechi, L., Zhang, L., Chen, Y.-C., Li, M., Qin, H., Wu, X., Carlesso, N., Marcucci, G., Rockne, R. C., & Kuo, Y.-H. (2022). Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition. *Science Advances*, 8, eabj1664. <https://www.science.org>
- Fu, S., Wang, Y., Xia, X., & Zheng, J. C. (2020). Exosome engineering: current progress in cargo loading and targeted delivery. *NanoImpact*, 20. DOI: <https://doi.org/10.1016/j.impact.2020.100261>
- Fu, X. I. F., Zhao, H. A. I. C., Yang, C. L. I., & Chen, C. Z. (2021). MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor. *Oncology Letters*, 2, 1–10. DOI: <https://doi.org/10.3892/ol.2021.12887>
- Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Rocco, E. G., Criscitiello, C., Malapelle, U., & Invernizzi, M. (2020). PTEN alterations and their role in cancer management: are we making headway on precision medicine?. *Genes*, 11(7), 1–19. DOI: <https://doi.org/10.3390/genes11070719>
- Gao, L., Wu, Z. X., Assaraf, Y. G., Chen, Z. S., & Wang, L. (2021). Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. *Drug Resistance Updates*, 57. DOI: <https://doi.org/10.1016/j.drug.2021.100770>

- Gao, R., Li, Q., Qiu, M., Xie, S., Sun, X., & Huang, T. (2023). Serum exosomal miR-192 serves as a potential detective biomarker for early pregnancy screening in sows. *Animal Bioscience*, 36(9), 1336–1349. DOI: <https://doi.org/10.5713/ab.22.0422>
- Gao, S., Guo, W., Liu, T., Liang, N., Ma, Q., Gao, Y., Tan, F., Xue, Q., & He, J. (2022). Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. *Cancer Science*, 113(2), 648–659. DOI: <https://doi.org/10.1111/cas.15222>
- Gao, X., Shen, K., Wang, C., Ling, J., Wang, H., Fang, Y., Shi, Y., Hou, Y., Qin, J., Sun, Y., & Qin, X. (2014). MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors. *Acta Biochimica et Biophysica Sinica*, 46(1), 72–75. DOI: <https://doi.org/10.1093/abbs/gmt118>
- García-Chico, C., López-Ortiz, S., Peñín-Grandes, S., Pinto-Fraga, J., Valenzuela, P. L., Emanuele, E., Ceci, C., Graziani, G., Fiuza-Luces, C., Lista, S., Lucia, A., & Santos-Lozano, A. (2023). Physical exercise and the hallmarks of breast cancer: a narrative review. *Cancers*, 15(1). DOI: <https://doi.org/10.3390/cancers15010324>
- García-Concejo, A., Sánchez-Quirós, B., Gómez-Sánchez, E., Sánchez-de Prada, L., Tamayo-Velasco, Á., Tovar-Doncel, M. S., Lorenzo, M., Gómez-Pesquera, E., Poves-Álvarez, R., Bernardo, D., Martín-Fernández, M., Gonzalo-Benito, H., Moreno-Portales, P., Prieto-Utrera, R., Bardají-Carrillo, M., López-Herrero, R., Fernández Arranz, M., Calaveras-Fernández, R., Tomillo-Cebrián, F., ... Tamayo, E. (2025). Study on the diagnostic role of exosome-derived miRNAs in postoperative septic shock and non-septic shock patients. *Critical Care*, 29(1). DOI: <https://doi.org/10.1186/s13054-025-05320-y>
- Garrana, S. H., Dagogo-Jack, I., Cobb, R., Kuo, A. H., Mendoza, D. P., Zhang, E. W., Heeger, A., Sequist, L. V., & Digumarthy, S. R. (2021). Clinical and imaging features of non-small-cell lung cancer in young patients. *Clinical Lung Cancer*, 22(1), 23–31. DOI: <https://doi.org/10.1016/j.clcc.2020.10.012>
- Gately, K., Forde, L., Gray, S., Morris, D., Corvin, A., Tewari, P., & O'byrne, K. (2015). Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. *Molecular and Clinical Oncology*, 3(5), 1073–1079. DOI: <https://doi.org/10.3892/mco.2015.580>
- Ge, Q., Zhou, Y., Lu, J., Bai, Y., Xie, X., & Lu, Z. (2014). MiRNA in plasma exosome is stable under different storage conditions. *Molecules*, 19(2), 1568–1575. DOI: <https://doi.org/10.3390/molecules19021568>
- Ge, Y., Wang, Y., Shao, W., Jin, J., Du, M., Ma, G., Chu, H., Wang, M., & Zhang, Z. (2016). Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers. *Scientific Reports*, 6. DOI: <https://doi.org/10.1038/srep33542>
- Ghafouri-Fard, S., Shoorei, H., Branicki, W., & Taheri, M. (2020). Non-coding RNA profile in lung cancer. *Experimental and Molecular Pathology*, 114. DOI: <https://doi.org/10.1016/j.yexmp.2020.104411>
- Gharib, A. F., Al-Shehri, S. S., Almalki, A., Alhazmi, A., Allahyani, M., Alghamdi, A., Alrehaili, A. A., Bakhuraysah, M. M., M., A. N. S., & Elsayy, W. H. (2024). Serum exosomal miR-874 as a potential biomarker for nonsmall cell lung cancer diagnosis and prognosis. *Indian Journal of Medical and Paediatric Oncology*. DOI: <https://doi.org/10.1055/s-0044-1790600>

- Ghorbani Alvanegh, A., Arpanaei, A., Esmaeili Gouvarchin Ghaleh, H., & Mohammad Ganji, S. (2024). MiR-320a upregulation contributes to the effectiveness of pemetrexed by inhibiting the growth and invasion of human lung cancer cell line (Calu-6). *Molecular Biology Reports*, 51(1). DOI: <https://doi.org/10.1007/s11033-024-09207-z>
- Gilson, P., Merlin, J. L., & Harlé, A. (2022). Deciphering tumour heterogeneity: from tissue to liquid biopsy. *Cancers*, 14(6), 1384. <https://doi.org/10.3390/cancers14061384>
- Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., & Caldas, C. (2010). Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, 16(5), 991–1006. DOI: <https://doi.org/10.1261/rna.1947110>
- Gkountakos, A., Sartori, G., Falcone, I., Piro, G., Ciuffreda, L., Carbone, C., Tortora, G., Scarpa, A., Bria, E., Milella, M., Rosell, R., Corbo, V., & Pilotto, S. (2019). Pten in lung cancer: dealing with the problem, building on new knowledge and turning the game around. *Cancers*, 11(8). DOI: <https://doi.org/10.3390/cancers11081141>
- Gon, Y., Shimizu, T., Mizumura, K., Maruoka, S., & Hikichi, M. (2020). Molecular techniques for respiratory diseases: microRNA and extracellular vesicles. *Respirology*, 25 (2), 149–160. DOI: <https://doi.org/10.1111/resp.13756>
- Gonda, A., Kabagwira, J., Senthil, G. N., & Wall, N. R. (2019). Internalization of exosomes through receptor-mediated endocytosis. *Molecular Cancer Research*, 17(2), 337–347. DOI: <https://doi.org/10.1158/1541-7786.MCR-18-0891>
- Greten, F. R., & Grivennikov, S. I. (2019). Inflammation and cancer: triggers, mechanisms, and consequences. *Immunity*, 15(1), 27–41. DOI: <https://doi.org/10.1016/j.immuni.2019.06.025>
- Grillone, K., Riillo, C., Riillo, C., Scionti, F., Rocca, R., Rocca, R., Tradigo, G., Guzzi, P. H., Alcaro, S., Di Martino, M. T., Tagliaferri, P., Tagliaferri, P., & Tassone, P. (2020). Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter.” *Journal of Experimental and Clinical Cancer Research*, 39(1). DOI: <https://doi.org/10.1186/s13046-020-01622-x>
- Grimolizzi, F., Monaco, F., Leoni, F., Bracci, M., Staffolani, S., Bersaglieri, C., Gaetani, S., Valentino, M., Amati, M., Rubini, C., Saccucci, F., Neuzil, J., Tomasetti, M., & Santarelli, L. (2017). Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. *Scientific Reports*, 7(1). DOI: <https://doi.org/10.1038/s41598-017-15475-6>
- Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. *Cell*, 140(6), 883–899. DOI: <https://doi.org/10.1016/j.cell.2010.01.025>
- Grzmil, M., & Hemmings, B. A. (2012). Translation regulation as a therapeutic target in cancer. *Cancer Research*, 72(16), 3891–3900. DOI: <https://doi.org/10.1158/0008-5472.CAN-12-0026>
- Grzywa, T. M., Klicka, K., & Włodarski, P. K. (2020). Regulators at every step—how microRNAs drive tumor cell invasiveness and metastasis. *Cancers*, 12(12), 1–54. DOI: <https://doi.org/10.3390/cancers12123709>
- Gu, W., Shi, J., Liu, H., Zhang, X., Zhou, J. J., Li, M., Zhou, D., Li, R., Lv, J., Wen, G., Zhu, S., Qi, T., Li, W., Wang, X., Wang, Z., Zhu, H., Zhou, C., Knox, K. S., Wang,

- T., ... Zhou, T. (2020). Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer. *Molecular Cancer*, 19(1). DOI: <https://doi.org/10.1186/s12943-020-01280-9>
- Gu, Y., Tang, S., Wang, Z., Cai, L., Lian, H., Shen, Y., & Zhou, Y. (2021). A pan-cancer analysis of the prognostic and immunological role of β -actin (ACTB) in human cancers. *Bioengineered*, 12(1), 6166–6185. DOI: <https://doi.org/10.1080/21655979.2021.1973220>
- Guo, C., Liu, S., Wang, J., Sun, M. Z., & Greenaway, F. T. (2013). ACTB in cancer. *Clinica Chimica Acta*, 417, 39–44. DOI: <https://doi.org/10.1016/j.cca.2012.12.012>
- Guo, H., Zhou, C., Zheng, M., Zhang, J., Wu, H., He, Q., Ding, L., & Yang, B. (2024). Insights into the role of derailed endocytic trafficking pathway in cancer: from the perspective of cancer hallmarks. *Pharmacological Research*, 201. DOI: <https://doi.org/10.1016/j.phrs.2024.107084>
- Guo, J. Y., & White, E. (2016). Autophagy, metabolism, and cancer. *Cold Spring Harbor Symposia on Quantitative Biology*, 81(1), 73–78. DOI: <https://doi.org/10.1101/sqb.2016.81.030981>
- Guo, J., Zhong, L., & Momeni, M. R. (2024). MicroRNA-155 and its exosomal form: small pieces in the gastrointestinal cancers puzzle. *Cell Biology and Toxicology*, 40(1). DOI: <https://doi.org/10.1007/s10565-024-09920-2>
- Guo, S., Chen, J., Chen, F., Zeng, Q., Liu, W. L., & Zhang, G. (2021). Exosomes derived from *Fusobacterium nucleatum* -infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16. *Gut*, 70(8), 1507–1519. DOI: <https://doi.org/10.1136/gutjnl-2020-321187>
- Guo, Y., Wang, G., Wang, Z., Ding, X., Qian, L., Li, Y., Ren, Z., Liu, P., Ma, W., Li, D., Li, Y., Zhao, Q., Lü, J., Li, Q., Wang, Q., & Yu, Z. (2021). Reck-notch1 signaling mediates miR-221/222 regulation of lung cancer stem cells in NSCLC. *Frontiers in Cell and Developmental Biology*, 9. DOI: <https://doi.org/10.3389/fcell.2021.663279>
- Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019). Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. *Cell Stem Cell*, 24(1), 65–78. DOI: <https://doi.org/10.1016/j.stem.2018.11.011>
- Gurung, S., Perocheau, D., Touramanidou, L., & Baruteau, J. (2021). The exosome journey: from biogenesis to uptake and intracellular signalling. *Cell Communication and Signaling*, 19(1). DOI: <https://doi.org/10.1186/s12964-021-00730-1>
- Gyamfi, J., Kim, J., & Choi, J. (2022). Cancer as a metabolic disorder. *International Journal of Molecular Sciences*, 23(3). DOI: <https://doi.org/10.3390/ijms23031155>
- Hajian-Tilaki, K. (2013). Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. *Caspian J Intern Med*, 4(2).
- Hajian-Tilaki, K. (2014). Sample size estimation in diagnostic test studies of biomedical informatics. *Journal of Biomedical Informatics*, 48, 193–204. DOI: <https://doi.org/10.1016/j.jbi.2014.02.013>
- Hallberg, B., & Palmer, R. H. (2013). Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. *Nature Reviews Cancer*, 13(10), 685–700. DOI: <https://doi.org/10.1038/nrc3580>

- Hamada, S., Matsumoto, R., & Masamune, A. (2022). HIF-1 and NRF2; key molecules for malignant phenotypes of pancreatic cancer. *Cancers*, 14(2). DOI: <https://doi.org/10.3390/cancers14020411>
- Han, J., Liu, Y., Yang, S., Wu, X., Li, H., & Wang, Q. (2021). MEK inhibitors for the treatment of non-small cell lung cancer. *Journal of Hematology and Oncology*, 14(1). DOI: <https://doi.org/10.1186/s13045-020-01025-7>
- Han, M. T. T., Pornprasert, S., Saeteng, S., Tantraworasin, A., Siwachat, S., Thuropathum, P., Chewaskulyong, B., & Cressey, R. (2023). Small RNA Deep Sequencing of Circulating RNAs Discovers a Unique Panel of microRNAs as Feasible and Reliable Biomarkers of Non-Small Cell Lung Cancers in Northern Thailand. *Asian Pacific Journal of Cancer Prevention*, 24(10), 3585–3598. DOI: <https://doi.org/10.31557/APJCP.2023.24.10.3585>
- Han, Q. F., Li, W. J., Hu, K. S., Gao, J., Zhai, W. L., Yang, J. H., & Zhang, S. J. (2022). Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. *Molecular Cancer*, 21(1). DOI: <https://doi.org/10.1186/s12943-022-01671-0>
- Han, X., Tan, Q., Yang, S., Li, J., Xu, J., Hao, X., Hu, X., Xing, P., Liu, Y., Lin, L., Gui, L., Qin, Y., Yang, J., Liu, P., Wang, X., Dai, W., Lin, D., Lin, H., & Shi, Y. (2019). Comprehensive profiling of gene copy number alterations predicts patient prognosis in resected stages I–III lung adenocarcinoma. *Frontiers in Oncology*, 9. DOI: <https://doi.org/10.3389/fonc.2019.00556>
- Han, Y., & Li, H. (2018). miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC). *Journal of Thoracic Disease*, 10(5), 3119–3131. DOI: <https://doi.org/10.21037/jtd.2018.05.32>
- Hanahan, D. (2022). Hallmarks of cancer: new dimensions. *Cancer Discovery*, 12(1), 31–46. DOI: <https://doi.org/10.1158/2159-8290.CD-21-1059>
- Hanley, J. A., & Mcneil, B. J. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*, 143(1), 29–36.
- Hao, X., Xin, R., & Dong, W. (2020). Decreased serum exosomal miR-320a expression is an unfavorable prognostic factor in patients with hepatocellular carcinoma. *Journal of International Medical Research*, 48(4). DOI: <https://doi.org/10.1177/0300060519896144>
- Hassanin, A. A. I., & Ramos, K. S. (2024). Circulating exosomal miRNA profiles in non-small cell lung cancers. *Cells*, 13(18). DOI: <https://doi.org/10.3390/cells13181562>
- Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., Yatabe, Y., Kawahara, K., Sekido, Y., & Takahashi, T. (2005). A polycistronic MicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Research*, 65(21), 9628–9632. DOI: <https://doi.org/10.1158/0008-5472.CAN-05-2352>
- He, X., Park, S., Chen, Y., & Lee, H. (2021). Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy. *Frontiers in Molecular Biosciences*, 8. DOI: <https://doi.org/10.3389/fmolb.2021.630718>
- Heegaard, N. H. H., Schetter, A. J., Welsh, J. A., Yoneda, M., Bowman, E. D., & Harris, C. C. (2012). Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. *International Journal of Cancer*, 130(6), 1378–1386. DOI: <https://doi.org/10.1002/ijc.26153>

- Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019). The microbiome, cancer, and cancer therapy. *Nature Medicine*, 25(3), 377–388. DOI: <https://doi.org/10.1038/s41591-019-0377-7>
- Herath, S., Sadeghi Rad, H., Radfar, P., Ladwa, R., Warkiani, M., O’Byrne, K., & Kulasinghe, A. (2022). the role of circulating biomarkers in lung cancer. *Frontiers in Oncology*, 11. DOI: <https://doi.org/10.3389/fonc.2021.801269>
- Hermes, G. L., Delgado, B., Tretiakova, M., Cavigelli, S. A., Krausz, T., Conzen, S. D., & McClintock, M. K. (2009). Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. *PNAS*, 106(52), 22393–22398.
- Hessvik, N. P., & Llorente, A. (2018). Current knowledge on exosome biogenesis and release. *Cellular and Molecular Life Sciences*, 75(2), 193–208. DOI: <https://doi.org/10.1007/s00018-017-2595-9>
- Hessvik, N. P., Phuyal, S., Brech, A., Sandvig, K., & Llorente, A. (2012). Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. *Biochimica et Biophysica Acta - Gene Regulatory Mechanisms*, 1819(11–12), 1154–1163. DOI: <https://doi.org/10.1016/j.bbagr.2012.08.016>
- Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021). Inflammation-induced tumorigenesis and metastasis. *International Journal of Molecular Sciences*, 22(11). DOI: <https://doi.org/10.3390/ijms22115421>
- Hill, R., Cautain, B., De Pedro, N., & Link, W. (2013). Targeting nucleocytoplasmic transport in cancer therapy. *Oncotarget*, 5(1). DOI: www.impactjournals.com/oncotarget/
- Hirschberger, S., Hinske, L. C., & Kreth, S. (2018). MiRNAs: dynamic regulators of immune cell functions in inflammation and cancer. *Cancer Letters*, 431, 11–21. DOI: <https://doi.org/10.1016/j.canlet.2018.05.020>
- Hofmann, L., Ludwig, S., Vahl, J. M., Brunner, C., Hoffmann, T. K., & Theodoraki, M. N. (2020). The emerging role of exosomes in diagnosis, prognosis, and therapy in head and neck cancer. *International Journal of Molecular Sciences*, 21(11), 1–22. DOI: <https://doi.org/10.3390/ijms21114072>
- Homer, R. J. (2015). Pathologists’ staging of multiple foci of lung cancer: poor concordance in absence of dramatic histologic or molecular differences. *American Journal of Clinical Pathology*, 143(5), 701–706. DOI: <https://doi.org/10.1309/AJCPNBWF55VGKOW>
- Hong, H., Yao, S., Zhang, Y., Ye, Y., Li, C., Hu, L., Sun, Y., Huang, H. Y., & Ji, H. (2020). In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor. *PLoS Genetics*, 16(11). DOI: <https://doi.org/10.1371/journal.pgen.1009168>
- Hou, H., Sun, D., & Zhang, X. (2019). The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. *Cancer Cell International*, 19 (1). DOI: <https://doi.org/10.1186/s12935-019-0937-4>
- Hou, J., Karin, M., & Sun, B. (2021). Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age? *Nature Reviews Clinical Oncology*, 18(5), 261–279. DOI: <https://doi.org/10.1038/s41571-020-00459-9>

- Hsu, Y. L., Hung, J. Y., Chang, W. A., Lin, Y. S., Pan, Y. C., Tsai, P. H., Wu, C. Y., & Kuo, P. L. (2017). Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. *Oncogene*, 36(34), 4929–4942. DOI: <https://doi.org/10.1038/onc.2017.105>
- Hu, C., Chen, M., Jiang, R., Guo, Y., Wu, M., & Zhang, X. (2018). Exosome-related tumor microenvironment. *Journal of Cancer*, 9(17), 3084–3092. DOI: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134819/>
- Hu, C., Meiners, S., Lukas, C., Stathopoulos, G. T., & Chen, J. (2020). Role of exosomal microRNAs in lung cancer biology and clinical applications. *Cell Proliferation*, 53(6). DOI: <https://doi.org/10.1111/cpr.12828>
- Huang, R. sheng, Zheng, Y. liang, Li, C., Ding, C., Xu, C., & Zhao, J. (2018). MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2. *Life Sciences*, 199, 104–111. DOI: <https://doi.org/10.1016/j.lfs.2018.03.005>
- Huang, S., Hua, X., Kuang, M., Zhu, J., Mu, H., Tian, Z., Zheng, X., & Xie, Q. (2021). MiR-190 promotes malignant transformation and progression of human urothelial cells through CDKN1B inhibition. *Research Square*. DOI: <https://doi.org/10.21203/rs.3.rs-143766/v1>
- Hücker, S. M., Fehlmann, T., Werno, C., Weidele, K., Lüke, F., Schlenska-Lange, A., Klein, C. A., Keller, A., & Kirsch, S. (2021). Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells. *Nature Communications*, 12(1). DOI: <https://doi.org/10.1038/s41467-021-24611-w>
- Hurley, J., Roberts, D., Bond, A., Keys, D., & Chen, C. (2012). Stem-loop RT-qPCR for MicroRNA expression profiling. *Methods in Molecular Biology*, 822, 33–52. DOI: https://doi.org/10.1007/978-1-61779-427-8_3
- Hussen, B. M., Hidayat, H. J., Salihi, A., Sabir, D. K., Taheri, M., & Ghafouri-Fard, S. (2021). MicroRNA: a signature for cancer progression. *Biomedicine and Pharmacotherapy*, 138. DOI: <https://doi.org/10.1016/j.biopha.2021.111528>
- Hutchinson, B. D., Shroff, G. S., Truong, M. T., & Ko, J. P. (2019). Spectrum of lung adenocarcinoma. *Seminars in Ultrasound, CT and MRI*, 40(3), 255–264. DOI: <https://doi.org/10.1053/j.sult.2018.11.009>
- Inada, K., Okoshi, Y., Cho-Isoda, Y., Ishiguro, S., Suzuki, H., Oki, A., Tamaki, Y., Shimazui, T., Saito, H., Hori, M., Iijima, T., & Kojima, H. (2018). Endogenous reference RNAs for microRNA quantitation in formalin-fixed, paraffin-embedded lymph node tissue. *Scientific Reports*, 8(1). DOI: <https://doi.org/10.1038/s41598-018-24338-7>
- Inagaki, Y., & Tamiya, A. (2020). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. *Lung Cancer*, 148, 179–180. DOI: <https://doi.org/10.1016/j.lungcan.2020.06.001>
- Inamura, K. (2017). Lung cancer: understanding its molecular pathology and the 2015 who classification. *Frontiers in Oncology*, 7. DOI: <https://doi.org/10.3389/fonc.2017.00193>

- Inamura, K., & Ishikawa, Y. (2016). MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. *Journal of Clinical Medicine*, 5(3). DOI: <https://doi.org/10.3390/jcm5030036>
- Inoue, J., & Inazawa, J. (2021). Cancer-associated miRNAs and their therapeutic potential. *Journal of Human Genetics*, 66(9), 937–945. DOI: <https://doi.org/10.1038/s10038-021-00938-6>
- Ireland, A. S., Micinski, A. M., Kastner, D. W., Guo, B., Wait, S. J., Spainhower, K. B., Conley, C. C., Chen, O. S., Guthrie, M. R., Soltero, D., Qiao, Y., Huang, X., Tarapcsák, S., Devarakonda, S., Chalishazar, M. D., Gertz, J., Moser, J. C., Marth, G., Puri, S., ... Oliver, T. G. (2020). MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. *Cancer Cell*, 38(1), 60–78. DOI: <https://doi.org/10.1016/j.ccell.2020.05.001>
- Jadus, M. R., Natividad, J., Mai, A., Ouyang, Y., Lambrecht, N., Szabo, S., Ge, L., Hoa, N., & Dacosta-Iyer, M. G. (2012). Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. *Clinical and Developmental Immunology*. DOI: <https://doi.org/10.1155/2012/160724>
- Jannu, M., & Jinka, R. (2023). Liquid biopsy: a non-invasive tool to detect cancer at an early stage. *International Journal of Advanced Research*, 11(02), 234–250. DOI: <https://doi.org/10.21474/ijar01/16245>
- Jia, S., Zocco, D., Samuels, M. L., Chou, M. F., Chammas, R., Skog, J., Zarovni, N., Momen-Heravi, F., & Kuo, W. P. (2014). Emerging technologies in extracellular vesicle-based molecular diagnostics. *Expert Review of Molecular Diagnostics*, 14(3), 307–321. DOI: <https://doi.org/10.1586/14737159.2014.893828>
- Jia, Z., Jia, J., Yao, L., & Li, Z. (2022). Crosstalk of exosomal non-coding RNAs in the tumor microenvironment: novel frontiers. *Frontiers in Immunology*, 13. DOI: <https://doi.org/10.3389/fimmu.2022.900155>
- Jiang, J., Li, J., Zhou, X., Zhao, X., Huang, B., & Qin, Y. (2022). Exosomes Regulate the Epithelial–Mesenchymal Transition in Cancer. *Frontiers in Oncology*, 12. DOI: <https://doi.org/10.3389/fonc.2022.864980>
- Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2021). Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. *Acta Pharmaceutica Sinica B*, 11(10), 2983–2994. DOI: <https://doi.org/10.1016/j.apsb.2021.01.003>
- Jin, X., Chen, Y., Chen, H., Fei, S., Chen, D., Cai, X., Liu, L., Lin, B., Su, H., Zhao, L., Su, M., Pan, H., Shen, L., Xie, D., & Xie, C. (2017). Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. *Clinical Cancer Research*, 23(17), 5311–5319. DOI: <https://doi.org/10.1158/1078-0432.CCR-17-0577>
- Jing, C., Mao, X., Wang, Z., Sun, K., Ma, R., Wu, J., & Cao, H. (2018). Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer. *Molecular Medicine Reports*, 18(2), 2191–2197. DOI: <https://doi.org/10.3892/mmr.2018.9210>
- John, P., Pulanco, M. C., Galbo, P. M., Wei, Y., Ohaegbulam, K. C., Zheng, D., & Zang, X. (2022). The immune checkpoint B7x expands tumor-infiltrating Tregs and

- promotes resistance to anti-CTLA-4 therapy. *Nature Communications*, 13(1). DOI: <https://doi.org/10.1038/s41467-022-30143-8>
- Judd, J., Karim, N. A., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., Pai, S. G., Socinski, M. A., Nieva, J. J., Kim, C., Wozniak, A. J., Ikpeazu, C., de Lima Lopes, G., Spira, A. I., Korn, W. M., ... Borghaei, H. (2021a). Characterization of KRAS mutation subtypes in non-small cell lung cancer. *Molecular Cancer Therapeutics*, 20(12), 2577–2584. DOI: <https://doi.org/10.1158/1535-7163.MCT-21-0201>
- Judd, J., Karim, N. A., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., Pai, S. G., Socinski, M. A., Nieva, J. J., Kim, C., Wozniak, A. J., Ikpeazu, C., de Lima Lopes, G., Spira, A. I., Korn, W. M., ... Borghaei, H. (2021b). Characterization of KRAS mutation subtypes in non-small cell lung cancer. *Molecular Cancer Therapeutics*, 20(12), 2577–2584. DOI: <https://doi.org/10.1158/1535-7163.MCT-21-0201>
- Julian, L., & Olson, M. (2014). Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. *Small GTPases*, 5, 1–12. DOI: <https://doi.org/10.4161/sgtp.29846>
- Junker, K. (2022). Liquid biopsy to individualise therapy in advanced bladder cancer. *Aktuelle Urologie*, 53(2), 180–187. DOI: <https://doi.org/10.1055/a-1646-9568>
- Kaddai, V., Le Marchand-Brustel, Y., & Cormont, M. (2008). Rab proteins in endocytosis and Glut4 trafficking. *Acta Physiologica*, 192(1), 75–88. DOI: <https://doi.org/10.1111/j.1748-1716.2007.01787.x>
- Kahlert, C., & Kalluri, R. (2013). Exosomes in tumor microenvironment influence cancer progression and metastasis. *Journal of Molecular Medicine*, 91(4), 431–437. DOI: <https://doi.org/10.1007/s00109-013-1020-6>
- Kahnert, K., Kauffmann-Guerrero, D., & Huber, R. M. (2016). SCLC—state of the art and what does the future have in store?. *Clinical Lung Cancer*, 17(5), 325–333. DOI: <https://doi.org/10.1016/j.clcc.2016.05.014>
- Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. *Science*, 367, 6478. DOI: <https://doi.org/10.1126/science.aau6977>
- Kanaoka, R., Iinuma, H., Dejima, H., Sakai, T., Uehara, H., Matsutani, N., & Kawamura, M. (2018). Usefulness of plasma exosomal microRNA-451a as a noninvasive biomarker for early prediction of recurrence and prognosis of non-small cell lung cancer. *Oncology*, 94(5), 311–323. DOI: <https://doi.org/10.1159/000487006>
- Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X. G., Yan, Z., Sun, X., Wang, H., Wang, Q., Tsung, A., Billiar, T. R., Zeh, H. J., Lotze, M. T., & Tang, D. (2014). HMGB1 in health and disease. *Molecular Aspects of Medicine*, 40, 1–116. DOI: <https://doi.org/10.1016/j.mam.2014.05.001>
- Kang, R., Zhang, Q., Zeh, H. J., Lotze, M. T., & Tang, D. (2013). HMGB1 in cancer: good, bad, or both?. *Clinical Cancer Research*, 19(15), 4046–4057. DOI: <https://doi.org/10.1158/1078-0432.CCR-13-0495>
- Karimi, N., & Moghaddam, S. J. (2023). KRAS-mutant lung cancer: targeting molecular and immunologic pathways, therapeutic advantages and restrictions. *Cells*, 12, 749. DOI: <https://doi.org/10.3390/cells>
- Khan, A. Q., Rashid, K., AlAmodi, A. A., Agha, M. V., Akhtar, S., Hakeem, I., Raza, S. S., & Uddin, S. (2021). Reactive oxygen species (ROS) in cancer pathogenesis and

- therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. *Biomedicine and Pharmacotherapy*, 143. DOI: <https://doi.org/10.1016/j.biopha.2021.112142>
- Khan, I., & Steeg, P. S. (2021). Endocytosis: a pivotal pathway for regulating metastasis. *British Journal of Cancer*, 124 (1), 66–75. DOI: <https://doi.org/10.1038/s41416-020-01179-8>
- Khan, U., Chowdhury, S., Billah, M. M., Islam, K. M. D., Thorlacius, H., & Rahman, M. (2021). Neutrophil extracellular traps in colorectal cancer progression and metastasis. *International Journal of Molecular Sciences*, 22(14). DOI: <https://doi.org/10.3390/ijms22147260>
- Khandelwal, A., Sharma, U., Barwal, T. S., Seam, R. K., Gupta, M., Rana, M. K., Vasquez, K. M., & Jain, A. (2021). Circulating miR-320a acts as a tumor suppressor and prognostic factor in non-small cell lung cancer. *Frontiers in Oncology*, 11. DOI: <https://doi.org/10.3389/fonc.2021.645475>
- Khine, M. N., & Sakurai, K. (2023). Golgi-targeting anticancer natural products. *Cancers*, 15(7). DOI: <https://doi.org/10.3390/cancers15072086>
- Kim, H., Jang, H., Cho, H., Choi, J., Hwang, K. Y., Choi, Y., Kim, S. H., & Yang, Y. (2021). Recent advances in exosome-based drug delivery for cancer therapy. *Cancers*, 13(17). DOI: <https://doi.org/10.3390/cancers13174435>
- Kim, J. Y., Rhim, W. K., Yoo, Y. I., Kim, D. S., Ko, K. W., Heo, Y., Park, C. G., & Han, D. K. (2021). Defined MSC exosome with high yield and purity to improve regenerative activity. *Journal of Tissue Engineering*, 12. DOI: <https://doi.org/10.1177/20417314211008626>
- Kim, J., Yao, F., Xiao, Z., Sun, Y., & Ma, L. (2018). MicroRNAs and metastasis: small RNAs play big roles. *Cancer and Metastasis Reviews*, 37(1), 5–15. DOI: <https://doi.org/10.1007/s10555-017-9712-y>
- Kim, K. B., Kim, D. W., Kim, Y., Tang, J., Kirk, N., Gan, Y., Kim, B., Fang, B., Park, J. L., Zheng, Y., & Park, K. S. (2022). WNT5A-RHOA signaling is a driver of tumorigenesis and represents a therapeutically actionable vulnerability in small cell lung cancer. *Cancer Research*, 82(22), 4219–4233. DOI: <https://doi.org/10.1158/0008-5472.CAN-22-1170>
- Kitamura, H., Yazawa, T., Sato, H., Okudela, K., & Shimoyamada, H. (2009). Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. *Endocrine Pathology*, 20(2), 101–107. DOI: <https://doi.org/10.1007/s12022-009-9072-4>
- Kligerman, S., & Abbott, G. (2010). A radiologic review of the new TNM classification for lung cancer. *American Journal of Roentgenology*, 194(3), 562–573. DOI: <https://doi.org/10.2214/AJR.09.3354>
- Kneitz, B., Krebs, M., Kalogirou, C., Schubert, M., Joniau, S., Van Poppel, H., Lerut, E., Kneitz, S., Scholz, C. J., Ströbel, P., Gessler, M., Riedmiller, H., & Spahn, M. (2014). Survival in patients with high-risk prostate cancer is predicted by mir-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. *Cancer Research*, 74(9), 2591–2603. DOI: <https://doi.org/10.1158/0008-5472.CAN-13-1606>
- Kong, F., Li, Y., Guo, R., Yang, L., Di, J., He, L., Wang, Z., Liu, D., & Li, X. (2022). Liquid biopsy assay for pulmonary adenocarcinoma using supernatants from core-

- needle biopsy specimens. *Thoracic Cancer*, 13(12), 1822–1826. DOI: <https://doi.org/10.1111/1759-7714.14461>
- Kou, F., Sun, H., Wu, L., Li, B., Zhang, B., Wang, X., & Yang, L. (2020). TOP2A promotes lung adenocarcinoma cells malignant progression and predicts poor prognosis in lung adenocarcinoma. *Journal of Cancer*, 11(9), 2496–2508. DOI: <https://doi.org/10.7150/jca.41415>
- Kulkarni, B., Kirave, P., Gondaliya, P., Jash, K., Jain, A., Tekade, R. K., & Kalia, K. (2019). Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. *Drug Discovery Today*, 24(10), 2058–2067. DOI: <https://doi.org/10.1016/j.drudis.2019.06.010>
- Kumar, A., & Deep, G. (2020). Hypoxia in tumor microenvironment regulates exosome biogenesis: Molecular mechanisms and translational opportunities. *Cancer Letters*, 479, 23–30. DOI: <https://doi.org/10.1016/j.canlet.2020.03.017>
- Kumar, A. S., Rayala, S. K., & Venkatraman, G. (2018). Targeting IGF1R pathway in cancer with microRNAs: how close are we?. *RNA Biology*, 15(3), 320–326. DOI: <https://doi.org/10.1080/15476286.2017.1338240>
- Kwok, G. T., Zhao, J. T., Weiss, J., Mugridge, N., Brahmabhatt, H., MacDiarmid, J. A., Robinson, B. G., & Sidhu, S. B. (2017). Translational applications of microRNAs in cancer, and therapeutic implications. *Non-coding RNA Research*, 2 (3–4), 143–150. DOI: <https://doi.org/10.1016/j.ncrna.2017.12.002>
- Lababede, O., & Meziane, M. A. (2018). The eighth edition of tnm staging of lung cancer: reference chart and diagrams. *The Oncologist*, 23(7), 844–848. DOI: <https://doi.org/10.1634/theoncologist.2017-0659>
- Lanzetti, L., & Di Fiore, P. P. (2008). Endocytosis and cancer: an “insider” network with dangerous liaisons. *Traffic*, 9(12), 2011–2021. DOI: <https://doi.org/10.1111/j.1600-0854.2008.00816.x>
- Lazarus, D. R., & Ost, D. E. (2013). How and when to use genetic markers for nonsmall cell lung cancer. *Current Opinion in Pulmonary Medicine*, 19(4), 331–339. DOI: <https://doi.org/10.1097/MCP.0b013e328362075c>
- Lee, K. H., Kronbichler, A., Park, D. D. Y., Park, Y. M., Moon, H., Kim, H., Choi, J. H., Choi, Y. S., Shim, S., Lyu, I. S., Yun, B. H., Han, Y., Lee, D., Lee, S. Y., Yoo, B. H., Lee, K. H., Kim, T. L., Kim, H., Shim, J. S., ... Shin, J. Il. (2017). Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. *Autoimmunity Reviews*, 16(11), 1160–1173. DOI: <https://doi.org/10.1016/j.autrev.2017.09.012>
- Lee, L. J., Papadopoli, D., Jewer, M., del Rincon, S., Topisirovic, I., Lawrence, M. G., & Postovit, L. M. (2021). Cancer plasticity: the role of mrna translation. *Trends in Cancer*, 7(2), 134–145. DOI: <https://doi.org/10.1016/j.trecan.2020.09.005>
- Lee, S., & Schmitt, C. A. (2019). The dynamic nature of senescence in cancer. *Nature Cell Biology*, 21(1), 94–101. DOI: <https://doi.org/10.1038/s41556-018-0249-2>
- Lei, Z., Shi, H., Li, W., Yu, D., Shen, F., Yu, X., Lu, D., Sun, C., & Liao, K. (2018). MiR-185 inhibits non-small cell lung cancer cell proliferation and invasion through targeting of SOX9 and regulation of Wnt signaling. *Molecular Medicine Reports*, 17(1), 1742–1752. DOI: <https://doi.org/10.3892/mmr.2017.8050>
- Li, G., Samuel, S., Ehsan, S., Haq, U., Mubarak, A. S., Studenik, C. R., Islam, A., Aufy, M., Kadham, M. J., Kareem, A., Al-Azzawi, J., & Abdel-Maksoud, M. A. (2023).

- Characterizing the oncogenic importance and exploring gene-immune cells correlation of ACTB in human cancers. *Am J Cancer Res*, 13(3).
- Li, H., Zhao, Q., & Tang, Z. (2021). LncRNA RP11-116G8.5 promotes the progression of lung squamous cell carcinoma through sponging miR-3150b-3p/miR-6870-5p to upregulate PHF12/FOXP4. *Pathology Research and Practice*, 226. DOI: <https://doi.org/10.1016/j.prp.2021.153566>
- Li, J., Gong, W., Zhu, W., Shao, X., & Zhang, C. (2017). The functional role of exosome microRNAs in lung cancer. *Open Life Sciences*, 12(1), 223–227. DOI: <https://doi.org/10.1515/biol-2017-0026>
- Li, J., Zhao, Y., & Wang, J. (2021). Extracellular vesicle-associated microRNA-221-3p secreted by drug-resistant lung cancer cells targets HMBOX1 to promote the progression of lung cancer. *Cancer Gene Therapy*, 28(6), 679–692. DOI: <https://doi.org/10.1038/s41417-020-00249-6>
- Li, M., Li, T., Ma, W., Wang, X., & Zhao, G. (2020). MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. *Oncology Letters*, 19(2), 1418–1426. DOI: <https://doi.org/10.3892/ol.2019.11246>
- Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y. Q., Luo, Q., Wang, L., Song, G. Bin, Sheng, J. P., & Xu, B. (2024). Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. *Signal Transduction and Targeted Therapy*, 9(1). DOI: <https://doi.org/10.1038/s41392-024-01953-7>
- Li, W., & Ruan, K. (2009). MicroRNA detection by microarray. *Analytical and Bioanalytical Chemistry*, 394(4), 1117–1124. DOI: <https://doi.org/10.1007/s00216-008-2570-2>
- Li, X., Liu, M., Liu, H., & Chen, J. (2022). Tumor metabolic reprogramming in lung cancer progression (Review). *Oncology Letters*, 24(2). DOI: <https://doi.org/10.3892/ol.2022.13407>
- Li, Y., Ma, H.-B., Shi, C.-Y., Feng, F.-L., & Yang, L. (2019). Mutant ACTB mRNA 3'UTR promotes hepatocellular carcinoma development by regulating miR-1 and miR-29a. DOI: <https://doi.org/10.1101/691527>
- Li, Y., Wang, Z., Li, Y., & Jing, R. (2017). MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer. *Oncology Letters*, 13(5), 3896–3904. DOI: <https://doi.org/10.3892/ol.2017.5888>
- Li, Y., Wang, Z., Zhao, F., Zeng, J., & Yang, X. (2022). MicroRNA-190b expression predicts a good prognosis and attenuates the malignant progression of pancreatic cancer by targeting MEF2C and TCF4. *Oncology Reports*, 47(1). DOI: <https://doi.org/10.3892/or.2021.8223>
- Liang, S., Wang, H., Zhang, Y., Tian, H., Li, C., & Hua, D. (2024). Prognostic implications of combining EGFR-TKIs and radiotherapy in stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: a real-world study. *Cancer Medicine*, 13(8). DOI: <https://doi.org/10.1002/cam4.7208>
- Liao, J., Shen, J., Leng, Q., Qin, M., Zhan, M., & Jiang, F. (2020). MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC). *Thoracic Cancer*, 11(3), 762–768. DOI: <https://doi.org/10.1111/1759-7714.13337>
- Lim, W., Ridge, C. A., Nicholson, A. G., & Mirsadraee, S. (2018). The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical

- implications. *Quantitative Imaging in Medicine and Surgery*, 8(7), 709–718. DOI: <https://doi.org/10.21037/qims.2018.08.02>
- Lim, Z. F., & Ma, P. C. (2019). Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. *Journal of Hematology and Oncology*, 12(1). DOI: <https://doi.org/10.1186/s13045-019-0818-2>
- Lin, R. K., Hsieh, Y. S., Lin, P., Hsu, H. S., Chen, C. Y., Tang, Y. A., Lee, C. F., & Wang, Y. C. (2010). The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. *Journal of Clinical Investigation*, 120(2), 521–532. DOI: <https://doi.org/10.1172/JCI40706>
- Ling, H. Y., Ou, H. S., Feng, S. D., Zhang, X. Y., Tuo, Q. H., Chen, L. X., Zhu, B. Y., Gao, Z. P., Tang, C. K., Yin, W. D., Zhang, L., & Liao, D. F. (2009). Changes in microRNA (miR) profile and effects of miR-320 in insulin-resistant 3t3-l1 adipocytes. *Clinical and Experimental Pharmacology and Physiology*, 36(9). DOI: <https://doi.org/10.1111/j.1440-1681.2009.05207.x>
- Liu, D., Mei, X., Wang, L., & Yang, X. (2017). RhoA inhibits apoptosis and increases proliferation of cultured SPCA1 lung cancer cells. *Molecular Medicine Reports*, 15(6), 3963–3968. DOI: <https://doi.org/10.3892/mmr.2017.6545>
- Liu, G., Xu, Z., Ge, Y., Jiang, B., Groen, H., Vliegenthart, R., & Xie, X. (2020). 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. *Translational Lung Cancer Research*, 9(4), 1212–1224. DOI: <https://doi.org/10.21037/tlcr-20-122>
- Liu, M., Lang, N., Chen, X., Tang, Q., Liu, S., Huang, J., Zheng, Y., & Bi, F. (2011). MiR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. *Cancer Letters*, 301(2), 151–160. DOI: <https://doi.org/10.1016/j.canlet.2010.11.009>
- Liu, W., Powell, C. A., & Wang, Q. (2022). Tumor microenvironment in lung cancer-derived brain metastasis. *Chinese Medical Journal*, 135(15), 1781–1791. DOI: <https://doi.org/10.1097/CM9.0000000000002127>
- Liu, Y., Wu, L., Ao, H., Zhao, M., Leng, X., Liu, M., Ma, J., & Zhu, J. (2019). Prognostic implications of autophagy-associated gene signatures in non-small cell lung cancer. *Aging*, 11 (23): 11440–11462. DOI: <https://doi.org/10.18632/aging.102544>
- Ljungström, M., & Oltra, E. (2025). Methods for extracellular vesicle isolation: relevance for encapsulated miRNAs in disease diagnosis and treatment. *Genes*, 16(3), 20–23. DOI: <https://doi.org/10.3390/genes16030330>
- Long, J., Ou, C., Xia, H., Zhu, Y., & Liu, D. (2015). MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression. *Tumor Biology*, 36(11), 8697–8702. DOI: <https://doi.org/10.1007/s13277-015-3623-8>
- Long, L., Zhang, X., Bai, J., Li, Y., Wang, X., & Zhou, Y. (2019). Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications. *Cancer Management and Research*, 11, 4413–4424. DOI: <https://doi.org/10.2147/CMAR.S198966>
- Lu, M., Hu, C., Wu, F., Shu, L., Pan, Y., Liu, X., Liu, P., Ma, F., Deng, C., & Huang, M. (2020). MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: a comprehensive analysis based

- on microarray data. *Lung Cancer*, 147, 193–197. DOI: <https://doi.org/10.1016/j.lungcan.2020.06.020>
- Lu, W., Li, S., Liu, B., Li, Y., Luo, M., Sun, L., You, J., & Zhou, Q. (2011). Screening of metastasis-related microRNAs in the large-cell lung cancer cell lines with different metastatic potentials. *Chinese Journal of Lung Cancer*, 14 (11), 835–840. DOI: <https://doi.org/10.3779/j.issn.1009-3419.2011.11.01>
- Ludwig, N., Whiteside, T. L., & Reichert, T. E. (2019). Challenges in exosome isolation and analysis in health and disease. *International Journal of Molecular Sciences*, 20(19). DOI: <https://doi.org/10.3390/ijms20194684>
- Luo, Z., Zhang, L., Li, Z., Li, X., Li, G., Yu, H., Jiang, C., Dai, Y., Guo, X., Xiang, J., & Li, G. (2012). An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. *BMC Medical Genomics*, 5. DOI: <https://doi.org/10.1186/1755-8794-5-3>
- Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019). Pten tumor-suppressor: the dam of stemness in cancer. *Cancers*, 11(8). DOI: <https://doi.org/10.3390/cancers11081076>
- Lv, J., & Song, Y. (2019). Could cell division cycle protein 42 be a target for lung cancer treatment?. *Translational Cancer Research*, 8(1), 312–318. DOI: <https://doi.org/10.21037/tcr.2019.01.13>
- Lv, L., Huang, R. han, Li, J., Xu, J., & Gao, W. (2022). Impact of NSCLC metabolic remodeling on immunotherapy effectiveness. *Biomarker Research*, 10(1). DOI: <https://doi.org/10.1186/s40364-022-00412-1>
- Lv, Q., Hu, J. X., Li, Y. J., Xie, N., Song, D. D., Zhao, W., Yan, Y. F., Li, B. S., Wang, P. Y., & Xie, S. Y. (2017). MiR-320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals. *Cancer Biology and Therapy*, 18(3), 142–151. DOI: <https://doi.org/10.1080/15384047.2017.1281497>
- Lv, X., Mao, Z., Sun, X., & Liu, B. (2023). Intratumoral heterogeneity in lung cancer. *Cancers*, 15(10). DOI: <https://doi.org/10.3390/cancers15102709>
- Lv, X., Yao, L., Zhang, J., Han, P., & Li, C. (2016). Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation via suppression of HK2-modulated glucose metabolism. *Molecular Medicine Reports*, 14(2), 1332–1338. DOI: <https://doi.org/10.3892/mmr.2016.5394>
- Ma, J., Bai, Y., Chen, F., Zhou, F., Zhang, L., Xue, P., & Wang, D. (2023). MicroRNA-185-5p targets tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta to regulate non-small cell lung cancer progression. *Journal of Cardiothoracic Surgery*, 18(1). DOI: <https://doi.org/10.1186/s13019-023-02342-x>
- Ma, W., Zhang, T., Pan, J., Shi, N., Fan, Q., Wang, L., & Lu, S. H. (2014). Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy. *Oncology Reports*, 32(4), 1601–1609. DOI: <https://doi.org/10.3892/or.2014.3348>
- Ma, X., Liu, H., Zhu, J., Zhang, C., Peng, Y., Mao, Z., Jing, Y., & Chen, F. (2022). MiR-185-5p regulates inflammation and phagocytosis through CDC42 /JNK pathway in macrophages. *Genes*, 13(3). DOI: <https://doi.org/10.3390/genes13030468>
- Maeda, H., Yao, H., Teape, D., & Dennery, P. A. (2022). Increased microRNA-34a contributes to hyperoxia-induced senescence in lung epithelial cells. *Lung*

- Development, and Neonatal Lung Disease*, A1978–A1978. DOI: <https://doi.org/10.1164/ajrccm>.
- Makise, M., Uchimura, R., Higashi, K., Mashiki, Y., Shiraishi, R., Shutoku, Y., & Kuniyasu, A. (2021). Overexpression of the nucleoporin Nup88 stimulates migration and invasion of HeLa cells. *Histochemistry and Cell Biology*, 156(5), 409–421. DOI: <https://doi.org/10.1007/s00418-021-02020-w>
- Manasa, V. G., & Kannan, S. (2017). Impact of microRNA dynamics on cancer hallmarks: an oral cancer scenario. *Tumor Biology*, 39 (3). DOI: <https://doi.org/10.1177/1010428317695920>
- Mao, L., Zhao, W., Li, X., Zhang, S., Zhou, C., Zhou, D., Ou, X., Xu, Y., Tang, Y., Ou, X., Hu, C., Ding, X., Luo, P., & Yu, S. (2021). Mutation spectrum of EGFR from 21,324 chinese patients with non-small cell lung cancer (NSCLC) successfully tested by multiple methods in a CAP-accredited laboratory. *Pathology and Oncology Research*, 27. DOI: <https://doi.org/10.3389/pore.2021.602726>
- Marcucci, G., Maharry, K. S., Metzeler, K. H., Volinia, S., Wu, Y. Z., Mrozek, K., Nicolet, D., Kohlschmidt, J., Whitman, S. P., Mendler, J. H., Schwind, S., Becker, H., Eisfeld, A. K., Carroll, A. J., Powell, B. L., Koltz, J. E., Garzon, R., Caligiuri, M. A., Stone, R. M., & Bloomfield, C. D. (2013). Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. *Journal of Clinical Oncology*, 31(17), 2086–2093. DOI: <https://doi.org/10.1200/JCO.2012.45.6228>
- Mardis, E. R. (2019). Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. *Genome Medicine*, 11(1). DOI: <https://doi.org/10.1186/s13073-019-0684-0>
- Marine, J. C., & Lozano, G. (2010). Mdm2-mediated ubiquitylation: P53 and beyond. *Cell Death and Differentiation*, 17(1), 93–102. DOI: <https://doi.org/10.1038/cdd.2009.68>
- Marino, F. Z., Bianco, R., Accardo, M., Ronchi, A., Cozzolino, I., Morgillo, F., Rossi, G., & Franco, R. (2019). Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. *International Journal of Medical Sciences*, 16(7), 981–989. DOI: <https://doi.org/10.7150/ijms.34739>
- Martín-López, J., Rojo, F., Martínez-Pozo, A., Hernández-Iglesias, T., Carcedo, D., de Alda, L. R., García, J. F., & Salas, C. (2023). Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the prospective central lung cancer biomarker registry (lungpath) from the spanish society of pathology (SEAP). *Journal of Clinical Pathology*, 76(5), 327–332. DOI: <https://doi.org/10.1136/jclinpath-2021-208034>
- Masotti, A., Caputo, V., Da Sacco, L., Pizzuti, A., Dallapiccola, B., & Bottazzo, G. F. (2009). Quantification of small non-coding RNAs allows an accurate comparison of miRNA expression profiles. *Journal of Biomedicine and Biotechnology*. DOI: <https://doi.org/10.1155/2009/659028>
- Mellors, P., & Aggarwal, C. (2022). Leveraging liquid biopsy for comprehensive genomic profiling for patients with advanced non–small cell lung cancer. DOI: <https://doi.org/10.1200/adn.22.200816>
- Mendoza, P., Díaz, J., Silva, P., & Torres, V. A. (2014). Rab5 activation as a tumor cell migration switch. *Small GTPases*, 5. DOI: <https://doi.org/10.4161/sgtp.28195>

- Meng, W., Hao, Y., He, C., Li, L., & Zhu, G. (2019). Exosome-orchestrated hypoxic tumor microenvironment. *Molecular Cancer*, 18(1). DOI: <https://doi.org/10.1186/s12943-019-0982-6>
- Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., & Vandesompele, J. (2009). A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biology*, 10(6). DOI: <https://doi.org/10.1186/gb-2009-10-6-r64>
- Miao, H., Ren, Q., Li, H., Zeng, M., Chen, D., Xu, C., Chen, Y., & Wen, Z. (2022). Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma. *BMC Cancer*, 22(1). DOI: <https://doi.org/10.1186/s12885-022-09314-9>
- Min, H. Y., & Lee, H. Y. (2018). Oncogene-driven metabolic alterations in cancer. *Biomolecules and Therapeutics*, 26(1), 45–56. DOI: <https://doi.org/10.4062/biomolther.2017.211>
- Miska, E. A., Alvarez-Saavedra, E., Townsend, M., Yoshii, A., Šestan, N., Rakic, P., Constantine-Paton, M., & Horvitz, R. (2004). *Microarray analysis of microRNA expression in the developing mammalian brain*. <http://genomebiology.com/2004/5/9/R68>
- Miziak, P., Baran, M., Borkiewicz, L., Trombik, T., & Stepulak, A. (2024). Acetylation of Histone H3 in Cancer Progression and Prognosis. *International Journal of Molecular Sciences*, 25(20). DOI: <https://doi.org/10.3390/ijms252010982>
- Mogi, A., & Kuwano, H. (2011). TP53 mutations in nonsmall cell lung cancer. *Journal of Biomedicine and Biotechnology*. DOI: <https://doi.org/10.1155/2011/583929>
- Moon, B., & Chang, S. (2022). Exosome as a delivery vehicle for cancer therapy. *Cells*, 11(3). DOI: <https://doi.org/10.3390/cells11030316>
- Moon, S., Shin, D. W., Kim, S., Lee, Y. S., Mankhong, S., Yang, S. W., Lee, P. H., Park, D. H., Kwak, H. B., Lee, J. S., & Kang, J. H. (2019). Enrichment of exosome-like extracellular vesicles from plasma suitable for clinical vesicular miRNA biomarker research. *Journal of Clinical Medicine*, 8(11), 1–16. DOI: <https://doi.org/10.3390/jcm8111995>
- Morana, O., Wood, W., & Gregory, C. D. (2022). The apoptosis paradox in cancer. *International Journal of Molecular Sciences*, 23(3). DOI: <https://doi.org/10.3390/ijms23031328>
- Moreno-Corona, N. C., de León-Bautista, M. P., León-Juárez, M., Hernández-Flores, A., Barragán-Gálvez, J. C., & López-Ortega, O. (2024). Rab GTPases, active members in antigen-presenting cells, and T lymphocytes. *Traffic*, 25(6). DOI: <https://doi.org/10.1111/tra.12950>
- Müller, S., Glaß, M., Singh, A. K., Haase, J., Bley, N., Fuchs, T., Lederer, M., Dahl, A., Huang, H., Chen, J., Posern, G., & Hüttelmaier, S. (2019). IGF2BP1 promotes SRF-dependent transcription in cancer in a m 6 A- and miRNA-dependent manner. *Nucleic Acids Research*, 47(1), 375–390. DOI: <https://doi.org/10.1093/nar/gky1012>
- Murphy, N. P., Mokhtar, A. M. B. A., Mott, H. R., & Owen, D. (2021). Molecular subversion of Cdc42 signalling in cancer. *Biochemical Society Transactions*, 49(3), 1425–1442. DOI: <https://doi.org/10.1042/BST20200557>

- Niu, Y., & Tang, G. (2019). MiR-185-5p targets rock2 and inhibits cell migration and invasion of hepatocellular carcinoma. *Oncology Letters*, 17(6), 5087–5093. DOI: <https://doi.org/10.3892/ol.2019.10144>
- Nurwidya, F., Andarini, S., Takahashi, F., Syahrudin, E., & Takahashi, K. (2016). Implications of insulin-like growth factor 1 receptor activation in lung cancer. *Malays J Med Sci*, 23(3), 9–21.
- O'Donoghue, E. J., & Krachler, A. M. (2016). Mechanisms of outer membrane vesicle entry into host cells. *Cellular Microbiology*, 18(11), 1508–1517. DOI: <https://doi.org/10.1111/cmi.12655>
- Ohno, S., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., Gotoh, N., & Kuroda, M. (2013). Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. *Molecular Therapy*, 21(1), 185–191. DOI: <https://doi.org/10.1038/mt.2012.180>
- Oropeza-de Lara, S. A., Garza-Veloz, I., Berthaud-González, B., Tirado-Navarro, T. G., Gurrola-Carlos, R., Bonilla-Rocha, B., Delgado-Enciso, I., & Martinez-Fierro, M. L. (2024). Comparative assessment of miR-185-5p and miR-191-5p expression: from normal endometrium to high-grade endometrial cancer. *Cells*, 13(13). DOI: <https://doi.org/10.3390/cells13131099>
- Óscar, R. G., Rafael, L. L., & Mercedes, S. C. M. (2022). Liquid biopsy-based microRNA models as potential biomarkers of bowel conditions. *Revista Espanola de Enfermedades Digestivas*, 115, 59–63. DOI: <https://doi.org/10.17235/REED.2022.9027/2022>
- Othman, N. (2012). Identification of bcl-xl induced micrnas involved in the apoptotic properties of human lung adenocarcinoma cells, a549.
- Othman, N., & Nagoor, N. H. (2017). MiR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2. *International Journal of Oncology*, 51(6), 1757–1764. DOI: <https://doi.org/10.3892/ijo.2017.4174>
- Ouyang, C., Wang, W., Wu, D., Wang, W., Ye, X., & Yang, Q. (2023). Analysis of serum exosome microRNAs in the rat model of chronic obstructive pulmonary disease. *American Journal of Translational Research*, 15(1), 138–150.
- Ouyang, T., Liu, Z., Han, Z., & Ge, Q. (2019). MicroRNA detection specificity: recent advances and future perspective. *Analytical Chemistry*, 91(5), 3179–3186. DOI: <https://doi.org/10.1021/acs.analchem.8b05909>
- Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., Mukherjee, A. G., Wanjari, U. R., Gopalakrishnan, A. V., & George, A. (2023). Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. *Genes and Diseases*, 10(3), 960–989. DOI: <https://doi.org/10.1016/j.gendis.2022.07.023>
- Pandey, S., & Yadav, P. (2025). Liquid biopsy in cancer management: Integrating diagnostics and clinical applications. *Practical Laboratory Medicine*, 43. DOI: <https://doi.org/10.1016/j.plabm.2024.e00446>
- Pandey, M., Mukhopadhyay, A., Sharawat, S. K., & Kumar, S. (2021). Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer. *Biochimica et*

- Biophysica Acta-Reviews on Cancer*, 1876(1). DOI: <https://doi.org/10.1016/j.bbcan.2021.188552>
- Panfoli, I., Bruschi, M., & Candiano, G. (2022). Exosomes: key tools for cancer liquid biopsy. *Biocell*, 46(10), 2167–2176. DOI: <https://doi.org/10.32604/biocell.2022.020154>
- Park, J., Wysocki, R. W., Amoozgar, Z., Maiorino, L., Fein, M. R., Jorns, J., Schott, A. F., Kinugasa-Katayama, Y., Lee, Y., Won, N. H., Nakasone, E. S., Hearn, S. A., Küttner, V., Qiu, J., Almeida, A. S., Perurena, N., Kessenbrock, K., Goldberg, M. S., & Egeblad, M. (2016). Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. *Science Translational Medicine*, 8(361). DOI: <https://doi.org/10.1126/scitranslmed.aag1711>
- Pang, W., Su, J., Wang, Y., Feng, H., Dai, X., Yuan, Y., Chen, X., & Yao, W. (2015). Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. *Cancer Science*, 106(10), 1362–1369. DOI: <https://doi.org/10.1111/cas.12747>
- Patergnani, S., Missiroli, S., Morciano, G., Perrone, M., Mantovani, C. M., Anania, G., Fiorica, F., Pinton, P., & Giorgi, C. (2021). Understanding the role of autophagy in cancer formation and progression is a real opportunity to treat and cure human cancers. *Cancers*, 13(22). DOI: <https://doi.org/10.3390/cancers13225622>
- Pauklin, S., Madrigal, P., Bertero, A., & Vallier, L. (2016). Initiation of stem cell differentiation involves cell cycle-dependent regulation of developmental genes by Cyclin D. *Genes*, 30, 421–433. DOI: <https://doi.org/10.1101/gad.271452>
- Pearson, C., Poirier, V., Fitzgerald, K., Rubin, G., & Hamilton, W. (2020). Cross-sectional study using primary care and cancer registration data to investigate patients with cancer presenting with non-specific symptoms. *BMJ Open*, 10(1). DOI: <https://doi.org/10.1136/bmjopen-2019-033008>
- Peng, X. X., Yu, R. Y., Wu, X., Wu, S. Y., Pi, C., Chen, Z. H., Zhang, X. C., Gao, C. Y., Shao, Y. W., Liu, L., Wu, Y. L., & Zhou, Q. (2020). Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. *Journal for ImmunoTherapy of Cancer*, 8(1). DOI: <https://doi.org/10.1136/jitc-2019-000376>
- Peng, Y., & Croce, C. M. (2016). The role of microRNAs in human cancer. *Signal Transduction and Targeted Therapy*, 1. DOI: <https://doi.org/10.1038/sigtrans.2015.4>
- Perez-Losada, J., Mao, J. H., & Balmain, A. (2005). Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. *Cancer Research*, 65(15), 6488–6492. DOI: <https://doi.org/10.1158/0008-5472.CAN-05-1294>
- Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020). ROS in cancer therapy: the bright side of the moon. *Experimental and Molecular Medicine*, 52(2), 192–203. DOI: <https://doi.org/10.1038/s12276-020-0384-2>
- Petrosyan, F., Daw, H., Haddad, A., Spiro, T., & Sood, R. (2015). Gene expression profiling for early-stage NSCLC. *American Journal of Clinical Oncology: Cancer Clinical Trials*, 38(1), 103–107. DOI: <https://doi.org/10.1097/COC.0b013e31828d95d8>

- Powrózek, T., Krawczyk, P., Kowalski, D. M., Kuźnar-Kamińska, B., Winiarczyk, K., Olszyna-Serementa, M., Batura-Gabryel, H., & Milanowski, J. (2016). Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer. *Tumor Biology*, 37(2), 2049–2055. DOI: <https://doi.org/10.1007/s13277-015-3971-4>
- Powrózek, T., Krawczyk, P., Kowalski, D. M., Winiarczyk, K., Olszyna-Serementa, M., & Milanowski, J. (2015). Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. *Translational Research*, 166(4), 315–323. DOI: <https://doi.org/10.1016/j.trsl.2015.05.009>
- Pradhan, R., Singhvi, G., Dubey, S. K., Gupta, G., & Dua, K. (2019). MAPK pathway: A potential target for the treatment of non-small-cell lung carcinoma. *Future Medicinal Chemistry*, 11(8), 793–795. DOI: <https://doi.org/10.4155/fmc-2018-0468>
- Pu, T., Sun, J., Ren, G., & Li, H. (2025). Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications. *Signal Transduction and Targeted Therapy*, 10(1). DOI: <https://doi.org/10.1038/s41392-025-02241-8>
- Qazi, R. e. M., Sajid, Z., Zhao, C., Hussain, I., Ifikhar, F., Jameel, M., Rehman, F. U., & Mian, A. A. (2023). Lyophilization based isolation of exosomes. *International Journal of Molecular Sciences*, 24(13). DOI: <https://doi.org/10.3390/ijms241310477>
- Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. *Signal Transduction and Targeted Therapy*, 5(1). DOI: <https://doi.org/10.1038/s41392-020-00313-5>
- Qin, X., Xu, H., Gong, W., & Deng, W. (2014). The tumor cytosol miRNAs, fluid miRNAs and exosome miRNAs in lung cancer. *Frontiers in Oncology*, 4, 1–7. DOI: <https://doi.org/10.3389/fonc.2014.00357>
- Qu, S., Fetsch, P., Thomas, A., Pommier, Y., Schrupp, D. S., Miettinen, M. M., & Chen, H. (2022). Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers. *Journal of Thoracic Oncology*, 17(1), 141–153. DOI: <https://doi.org/10.1016/j.jtho.2021.08.763>
- Rabinowits, G., Gerçel-Taylor, C., Day, J. M., Taylor, D. D., & Kloecker, G. H. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. *Clinical Lung Cancer*, 10(1), 42–46. DOI: <https://doi.org/10.3816/CLC.2009.n.006>
- Ragni, E., Colombini, A., De Luca, P., Libonati, F., Viganò, M., Perucca Orfei, C., Zagra, L., & de Girolamo, L. (2021). MiR-103a-3p and miR-22-5p are reliable reference genes in extracellular vesicles from cartilage, adipose tissue, and bone marrow cells. *Frontiers in Bioengineering and Biotechnology*, 9. DOI: <https://doi.org/10.3389/fbioe.2021.632440>
- Rahim, T., Aslam, S., Sohail, A., & Khan, M. J. (2024). Molecular role of miR-152-3p, miR-296-5p and miR-185-5p in urinary bladder cancer etiology. *Human Gene*, 42. DOI: <https://doi.org/10.1016/j.humgen.2024.201353>
- Rahman, M. M., Islam, M. R., Shohag, S., Ahasan, M. T., Sarkar, N., Khan, H., Hasan, A. M., Cavalu, S., & Rauf, A. (2022). Microbiome in cancer: role in carcinogenesis and impact in therapeutic strategies. *Biomedicine and Pharmacotherapy*, 149. DOI: <https://doi.org/10.1016/j.biopha.2022.112898>

- Rami-Porta, R. (2021). Future perspectives on the tnm staging for lung cancer. *Cancers*, 13(8). DOI: <https://doi.org/10.3390/cancers13081940>
- Rami-Porta, R., & Goldstraw, P. (2010). Strength and weakness of the new TNM classification for lung cancer. *European Respiratory Journal*, 36(2), 237–239. DOI: <https://doi.org/10.1183/09031936.00016210>
- Ramirez-Garrastacho, M., Bajo-Santos, C., Line, A., Martens-Uzunova, E. S., de la Fuente, J. M., Moros, M., Soekmadji, C., Tasken, K. A., & Llorente, A. (2021). Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research. *British Journal of Cancer*. 126, 331 – 350. DOI: <https://doi.org/10.1038/s41416-021-01610-8>
- Ramírez-Moya, J., & Santisteban, P. (2019). MiRNA-directed regulation of the main signaling pathways in thyroid cancer. *Frontiers in Endocrinology*, 10. DOI: <https://doi.org/10.3389/fendo.2019.00430>
- Rankin, E. B., Nam, J. M., & Giaccia, A. J. (2016). Hypoxia: Signaling the Metastatic Cascade. *Trends in Cancer*, 2(6), 295–304. DOI: <https://doi.org/10.1016/j.trecan.2016.05.006>
- Raso, M. G., Bota-Rabasedas, N., & Wistuba, I. I. (2021). Pathology and classification of SCLC. *Cancers*, 13(4), 1–11. DOI: <https://doi.org/10.3390/cancers13040820>
- Rufino-Palomares, E. E., Reyes-Zurita, F. J., Lupiáñez, J. A., & Medina, P. P. (2013). MicroRNAs as oncogenes and tumor suppressors. *MicroRNAs in Medicine*, 223–243. DOI: <https://doi.org/10.1002/9781118300312.ch14>
- Ruiz-Cordero, R., Ma, J., Khanna, A., Lyons, G., Rinsurongkawong, W., Bassett, R., Guo, M., Routbort, M. J., Zhang, J., Skoulidis, F., Heymach, J., Roarty, E. B., Tang, Z., Medeiros, L. J., Patel, K. P., Luthra, R., & Roy-Chowdhuri, S. (2020). Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. *BMC Cancer*, 20(1). DOI: <https://doi.org/10.1186/s12885-020-6579-z>
- Russo, S., Kwiatkowski, M., Govorukhina, N., Bischoff, R., & Melgert, B. N. (2021). Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. *Frontiers in Immunology*, 12. DOI: <https://doi.org/10.3389/fimmu.2021.746151>
- Ryan, B. M., Robles, A. I., McClary, A. C., Haznadar, M., Bowman, E. D., Pine, S. R., Brown, D., Khan, M., Shiraishi, K., Kohno, T., Okayama, H., Modali, R., Yokota, J., & Harris, C. C. (2015). Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer. *Cancer Research*, 75(3), 566–575. DOI: <https://doi.org/10.1158/0008-5472.CAN-14-2101>
- Sagini, K., Urbanelli, L., Buratta, S., Emiliani, C., & Llorente, A. (2023). Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis. *Pharmaceutics*, 15(2). DOI: <https://doi.org/10.3390/pharmaceutics15020437>
- Sanfiorenzo, C., Ilie, M. I., Belaid, A., Barlési, F., Mouroux, J., Marquette, C. H., Brest, P., & Hofman, P. (2013). Two panels of plasma micrnas as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. *PLoS One*, 8(1). DOI: <https://doi.org/10.1371/journal.pone.0054596>
- Santos, J. C., Profitós-Pelejá, N., Sánchez-Vinces, S., & Roué, G. (2023). RHOA therapeutic targeting in hematological cancers. *Cells*, 12(3). DOI: <https://doi.org/10.3390/cells12030433>

- Sarkar, D. K., Murugan, S., Zhang, C., & Boyadjieva, N. (2012). Regulation of cancer progression by β -endorphin neuron. *Cancer Research*, 72(4), 836–840. DOI: <https://doi.org/10.1158/0008-5472.CAN-11-3292>
- Schageman, J., Zeringer, E., Li, M., Barta, T., Lea, K., Gu, J., Magdaleno, S., Setterquist, R., & Vlassov, A. V. (2013). The complete exosome workflow solution: from isolation to characterization of RNA cargo. *BioMed Research International*. DOI: <https://doi.org/10.1155/2013/253957>
- Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckerth, F., Schüller, M., Koleczko, S., Michels, S., Fassunke, J., Pasternack, H., Heydt, C., Serke, M., Fischer, R., Schulte, W., ... Wolf, J. (2019). K-ras mutation subtypes in NSCLC and associated co-occurring mutations in other oncogenic pathways. *Journal of Thoracic Oncology*, 14(4), 606–616. DOI: <https://doi.org/10.1016/j.jtho.2018.12.013>
- Schmitt, C. A., Wang, B., & Demaria, M. (2022). Senescence and cancer — role and therapeutic opportunities. *Nature Reviews Clinical Oncology*, 19(10), 619–636. DOI: <https://doi.org/10.1038/s41571-022-00668-4>
- Seiler, C. L., Song, J. ung M., Kotandeniya, D., Chen, J., Kono, T. J. Y., Han, Q., Colwell, M., Auch, B., Sarver, A. L., Upadhyaya, P., Ren, Y., Faulk, C., De Flora, S., La Maestra, S., Chen, Y., Kassie, F., & Tretyakova, N. Y. (2020). Inhalation exposure to cigarette smoke and inflammatory agents induces epigenetic changes in the lung. *Scientific Reports*, 10(1). DOI: <https://doi.org/10.1038/s41598-020-67502-8>
- Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. *Nature Reviews Cancer*, 3(10), 721–732. DOI: <https://doi.org/10.1038/nrc1187>
- Seo, N., Akiyoshi, K., & Shiku, H. (2018). Exosome-mediated regulation of tumor immunology. *Cancer Science*, 109(10), 2998–3004. DOI: <https://doi.org/10.1111/cas.13735>
- Settayanon, S., Chanvorachote, P., & Mutirangura, A. (2025). The role of Box A of HMGB1 in producing γ H2AX associated DNA breaks in lung cancer. *Scientific Reports*, 15(1). DOI: <https://doi.org/10.1038/s41598-025-87773-3>
- Shen, J., Liu, Z., Todd, N. W., Zhang, H., Liao, J., Yu, L., Guarnera, M. A., Li, R., Cai, L., Zhan, M., & Jiang, F. (2011). Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. *BMC Cancer*, 11. DOI: <https://doi.org/10.1186/1471-2407-11-374>
- Shi, F., Wu, J., Jia, Q., Li, K., Li, W., Shi, Y., Wang, Y., & Wu, S. (2022). Relationship between the expression of ARHGAP25 and RhoA in non-small cell lung cancer and vasculogenic mimicry. *BMC Pulmonary Medicine*, 22(1). DOI: <https://doi.org/10.1186/s12890-022-02179-5>
- Shi, L., Xiao, R., Wang, M., Zhang, M., Weng, N., Zhao, X., Steven Zheng, X. F., Wang, H., & Mai, S. (2018). MicroRNA-342-3p suppresses proliferation and invasion of nasopharyngeal carcinoma cells by directly targeting Cdc42. *Oncology Reports*, 40(5), 2750–2757. DOI: <https://doi.org/10.3892/or.2018.6642>
- Shigeyasu, K., Toden, S., Zumwalt, T. J., Okugawa, Y., & Goel, A. (2017). Emerging role of microRNAs as liquid biopsy biomarkers in gastrointestinal cancers. *Clinical Cancer Research*, 23(10). DOI: <https://doi.org/10.1158/1078-0432.CCR-16-1676>

- Shirasawa, M., Fukui, T., Kusuhara, S., Hiyoshi, Y., Ishihara, M., Kasajima, M., Nakahara, Y., Otani, S., Igawa, S., Yokoba, M., Mitsufuji, H., Kubota, M., Katagiri, M., Sasaki, J., & Naoki, K. (2018). Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. *Cancer Management and Research*, 10, 6039–6047. DOI: <https://doi.org/10.2147/CMAR.S181789>
- Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021). Linking metabolic reprogramming, plasticity and tumor progression. *Cancers*, 13(4), 1–25. DOI: <https://doi.org/10.3390/cancers13040762>
- Shyer, J. A., Flavell, R. A., & Bailis, W. (2020). Metabolic signaling in T cells. *Cell Research*, 30(8), 649–659. DOI: <https://doi.org/10.1038/s41422-020-0379-5>
- Sinha, A., Zou, Y., Patel, A. S., Yoo, S., Jiang, F., Sato, T., Kong, R., Watanabe, H., Zhu, J., Massion, P. P., Borczuk, A. C., & Powell, C. A. (2022). Early-stage lung adenocarcinoma MDM2 Genomic amplification predicts clinical outcome and response to targeted therapy. *Cancers*, 14, 708. DOI: <https://doi.org/10.3390/cancers>
- Sinjab, A., Rahal, Z., & Kadara, H. (2022). Cell-by-cell: unlocking lung cancer pathogenesis. *Cancers*, 14(14). DOI: <https://doi.org/10.3390/cancers14143424>
- Soeroso, N. N., Ananda, F. R., Sitanggang, J. S., & Vinolina, N. S. (2022). The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. *F1000 Research*, 11. DOI: <https://doi.org/10.12688/f1000research.113303.1>
- Sohel, M. M. H. (2020). Circulating microRNAs as biomarkers in cancer diagnosis. *Life Sciences*, 248. DOI: <https://doi.org/10.1016/j.lfs.2020.117473>
- Soni, U. K., Jenny, L., & Hegde, R. S. (2023). IGF-1R targeting in cancer – does sub-cellular localization matter?. *Journal of Experimental and Clinical Cancer Research*, 42(1). DOI: <https://doi.org/10.1186/s13046-023-02850-7>
- Sorscher, S., LoPiccolo, J., Heald, B., Chen, E., Bristow, S. L., Michalski, S. T., Nielsen, S. M., Lacoste, A., Keyder, E., Lee, H., Nussbaum, R. L., Martins, R., & Esplin, E. D. (2023). Rate of pathogenic germline variants in patients with lung cancer. *JCO Precision Oncology*, 7. DOI: <https://doi.org/10.1200/po.23.00190>
- Sousa, C., Silva-Lima, B., & Videira, M. (2022). Akt/mTOR activation in lung cancer tumorigenic regulators and their potential value as biomarkers. *Oncology*, 2(1), 36–55. DOI: <https://doi.org/10.3390/onco2010004>
- Stasevich, E. M., Murashko, M. M., Zinevich, L. S., Demin, D. E., & Schwartz, A. M. (2021). The role of non-coding rnas in the regulation of the proto-oncogene myc in different types of cancer. *Biomedicines*, 9(8). DOI: <https://doi.org/10.3390/biomedicines9080921>
- Stutvoet, T. S., Kol, A., de Vries, E. G. E., de Bruyn, M., Fehrmann, R. S. N., Terwisscha van Scheltinga, A. G. T., & de Jong, S. (2019). MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. *Journal of Pathology*, 249(1), 52–64. DOI: <https://doi.org/10.1002/path.5280>
- Su, C. M., Weng, Y. S., Kuan, L. Y., Chen, J. H., & Hsu, F. T. (2020). Suppression of pkcδ/nf-kb signaling and apoptosis induction through extrinsic/intrinsic pathways are associated magnolol-inhibited tumor progression in colorectal cancer in vitro

- and in vivo. *International Journal of Molecular Sciences*, 21(10). DOI: <https://doi.org/10.3390/ijms21103527>
- Subat, S., Inamura, K., Ninomiya, H., Nagano, H., Okumura, S., & Ishikawa, Y. (2018). Unique microRNA and mRNA interactions in EGFR-mutated lung adenocarcinoma. *Journal of Clinical Medicine*, 7(11). DOI: <https://doi.org/10.3390/jcm7110419>
- Subbiah, V., Baik, C., & Kirkwood, J. M. (2020). Clinical development of BRAF plus MEK inhibitor combinations. *Trends in Cancer*, 6(9), 797–810. DOI: <https://doi.org/10.1016/j.trecan.2020.05.009>
- Sun, D., Qian, H., Li, J., & Xing, P. (2024). Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy. *Journal of Biomedical Science*, 31(1). DOI: <https://doi.org/10.1186/s12929-024-01004-x>
- Sun, G., Ding, X., Bi, N., Wang, Z., Wu, L., Zhou, W., Zhao, Z., Wang, J., Zhang, W., Fan, J., Zhang, W. J., Dong, X., Lv, N., Song, Y., Zhan, Q., & Wang, L. H. (2019). Molecular predictors of brain metastasis-related microRNAs in lung adenocarcinoma. *PLoS Genetics*, 15(2). DOI: <https://doi.org/10.1371/journal.pgen.1007888>
- Sun, L., Chen, Y., Su, Q., Tang, X., Liang, Y., Che, G., & Luo, F. (2016). Increased plasma miRNA-30a as a biomarker for non-small cell lung cancer. *Medical Science Monitor*, 22, 647–655. DOI: <https://doi.org/10.12659/MSM.897330>
- Sun, N., Ye, L., Chang, T., Li, X., & Li, X. (2014). MicroRNA-195-Cdc42 axis acts as a prognostic factor of esophageal squamous cell carcinoma. *Int J Clin Exp Pathol*, 7(10).
- Sur, D., Balacescu, L., Cainap, S. S., Visan, S., Pop, L., Burz, C., Havasi, A., Buiga, R., Cainap, C., Irimie, A., & Balacescu, O. (2021). Predictive efficacy of miR-125b-5p, miR-17-5p, and miR-185-5p in liver metastasis and chemotherapy response among advanced stage colorectal cancer patients. *Frontiers in Oncology*, 11. DOI: <https://doi.org/10.3389/fonc.2021.651380>
- Syeda, Z. A., Langden, S. S. S., Munkhzul, C., Lee, M., & Song, S. J. (2020). Regulatory mechanism of microRNA expression in cancer. *International Journal of Molecular Sciences*, 21(5). DOI: <https://doi.org/10.3390/ijms21051723>
- Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020). Targeting CDK2 in cancer: challenges and opportunities for therapy. *Drug Discovery Today*, 25(2), 406–413. DOI: <https://doi.org/10.1016/j.drudis.2019.12.001>
- Talikka, M., Sierro, N., Ivanov, N. V., Chaudhary, N., Peck, M. J., Hoeng, J., Coggins, C. R. E., & Peitsch, M. C. (2012). Genomic impact of cigarette smoke, with application to three smoking-related diseases. *Critical Reviews in Toxicology*, 42(10), 877–889. DOI: <https://doi.org/10.3109/10408444.2012.725244>
- Tan, A. C. (2022). The role of liquid biopsy in the diagnostic testing algorithm for advanced lung cancer. *Oncology*, 2(3), 181–185. DOI: <https://doi.org/10.3390/onco2030012>
- Tanabe, S. (2021). EMT mechanism, lung cancer metastasis, and microRNA. *Frontiers in Molecular Biosciences*, 8. DOI: <https://doi.org/10.3389/fmolb.2021.731788>

- Tang, E. R., Schreiner, A. M., & Pua, B. B. (2014). Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS). *Journal of Thoracic Disease*, 6, S489–S501. DOI: <https://doi.org/10.3978/j.issn.2072-1439.2014.09.12>
- Tang, F., Zhang, J. N., Zhao, X. L., Xu, L. Y., Ao, H., & Peng, C. (2025). Unlocking the dual role of autophagy: a new strategy for treating lung cancer. *Journal of Pharmaceutical Analysis*, 15(3). DOI: <https://doi.org/10.1016/j.jpha.2024.101098>
- Tang, S., Li, S., Liu, T., He, Y., Hu, H., Zhu, Y., Tang, S., & Zhou, H. (2021). MicroRNAs: emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer. *Cancer Letters*, 502, 71–83. DOI: <https://doi.org/10.1016/j.canlet.2020.12.040>
- Tang, S., Yu, S., Cheng, J., Zhang, Y., & Huang, X. (2020). The versatile roles and clinical implications of exosomal mRNAs and microRNAs in cancer. *International Journal of Biological Markers*, 35(2), 3–19. DOI: <https://doi.org/10.1177/1724600820920293>
- Tang, Y., Cui, Y., Li, Z., Jiao, Z., Zhang, Y., He, Y., Cheng, G., Zhou, Q., Wang, W., Zhou, X., Luo, J., & Zhang, S. (2016). Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. *Journal of Experimental and Clinical Cancer Research*, 35(1). DOI: <https://doi.org/10.1186/s13046-016-0285-3>
- Tepebaşı, M. Y., & Öztürk, Ö. (2023). miR-21, miR-221, and miR-222 upregulation in lung cancer promotes metastasis by reducing oxidative stress and apoptosis. *Revista Da Associacao Medica Brasileira*, 69(6). DOI: <https://doi.org/10.1590/1806-9282.20221688>
- Thankamony, A. P., Subbalakshmi, A. R., Jolly, M. K., & Nair, R. (2021). Lineage plasticity in cancer: the tale of a skin-walker. *Cancers*, 13(14). DOI: <https://doi.org/10.3390/cancers13143602>
- Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G. K., Ayre, D. C., Bach, J. M., Bachurski, D., Baharvand, H., Balaj, L., Baldacchino, S., Bauer, N. N., Baxter, A. A., Bebawy, M., ... Zuba-Surma, E. K. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*, 7(1). DOI: <https://doi.org/10.1080/20013078.2018.1535750>
- Thorburn, A., Thamm, D. H., & Gustafson, D. L. (2014). Autophagy and cancer therapy. *Molecular Pharmacology*, 85(6), 830–838. DOI: <https://doi.org/10.1124/mol.114.091850>
- Tian, B., Pang, Y., Gao, Y., Meng, Q., Xin, L., Sun, C., Tang, X., Wang, Y., Li, Z., Lin, H., & Wang, L. (2023). A pan-cancer analysis of the oncogenic role of golgi transport 1B in human tumors. *Journal of Translational Internal Medicine*, 11(4), 433–448. DOI: <https://doi.org/10.2478/jtim-2023-0002>
- Tian, F., Shen, Y., Chen, Z., Li, R., & Ge, Q. (2017). No significant difference between plasma miRNAs and plasma-derived exosomal miRNAs from healthy people. *BioMed Research International*, 1-5. DOI: <https://doi.org/10.1155/2017/1304816>

- Todd, J. L., Kelly, F. L., Neely, M. L., Keslar, K., Pavlisko, E. N., McCall, S. J., Fletcher, A., Chen, X., Frankel, C. W., Singer, L. G., Budev, M., Shah, P. D., Belperio, J. A., Snyder, L. D., Reynolds, J. M., Fairchild, R. L., & Palmer, S. M. (2020). NanoString gene expression profiling in chronic lung allograft dysfunction (CLAD). *The Journal of Heart and Lung Transplantation*, 39(4), S113. DOI: <https://doi.org/10.1016/j.healun.2020.01.985>
- Tomas, A., Futter, C. E., & Eden, E. R. (2014). EGF receptor trafficking: consequences for signaling and cancer. *Trends in Cell Biology*, 24(1), 26–34. DOI: <https://doi.org/10.1016/j.tcb.2013.11.002>
- Travis, W. D. (2011). Pathology of lung cancer. *Clinics in Chest Medicine*, 32(4), 669–692. DOI: <https://doi.org/10.1016/j.ccm.2011.08.005>
- Travis, W. D. (2014). Pathology of adenocarcinoma. *Lung Cancer: Fourth Edition*, 144–157. DOI: <https://doi.org/10.1002/9781118468791.ch8>
- Tsamis, I., Gomatou, G., Chachali, S. P., Trontzas, I. P., Patriarcheas, V., Panagiotou, E., & Kotteas, E. (2023). BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. *Clinical and Translational Oncology*, 25(1), 10–20. DOI: <https://doi.org/10.1007/s12094-022-02849-0>
- Turner, J. G., Dawson, J., Cubitt, C. L., Baz, R., & Sullivan, D. M. (2014). Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. *Seminars in Cancer Biology*, 27, 62–73. DOI: <https://doi.org/10.1016/j.semcancer.2014.03.001>
- Uliivi, P. (2023). Liquid biopsy as a tool for precision oncology: new challenges to assess clinical response. *Frontiers in Pharmacology*, 14. DOI: <https://doi.org/10.3389/fphar.2023.1192549>
- Valencia, K., Luis-Ravelo, D., Bovy, N., Antón, I., Martínez-Canarias, S., Zanduetta, C., Ormazábal, C., Struman, I., Tabruyn, S., Rebmann, V., De Las Rivas, J., Guruceaga, E., Bandrés, E., & Lecanda, F. (2014). MiRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. *Molecular Oncology*, 8(3), 689–703. DOI: <https://doi.org/10.1016/j.molonc.2014.01.012>
- Van Genugten, E. A. J., Weijers, J. A. M., Heskamp, S., Kneilling, M., van den Heuvel, M. M., Piet, B., Bussink, J., Hendriks, L. E. L., & Aarntzen, E. H. J. G. (2022). Imaging the rewired metabolism in lung cancer in relation to immune therapy. *Frontiers in Oncology*, 11. DOI: <https://doi.org/10.3389/fonc.2021.786089>
- Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., Xiao, L., Vannini, I., Redis, R. S., D'Abundo, L., Zhang, X., Nicoloso, M. S., Rossi, S., Gonzalez-Villasana, V., Rupaimoole, R., Ferracin, M., Morabito, F., Neri, A., Ruvolo, P. P., ... Calin, G. A. (2017). Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. *Clinical Cancer Research*, 23(11), 2891–2904. DOI: <https://doi.org/10.1158/1078-0432.CCR-16-1025>
- Van Schooneveld, E., Wouters, M. C. A., Van der Auwera, I., Peeters, D. J., Wildiers, H., Van Dam, P. A., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J. (2012). Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. *Breast Cancer Research*, 14(1). DOI: <https://doi.org/10.1186/bcr3127>

- Vanhove, K., Graulus, G. J., Mesotten, L., Thomeer, M., Derveaux, E., Noben, J. P., Guedens, W., & Adriaenssens, P. (2019). The metabolic landscape of lung cancer: new insights in a disturbed glucose metabolism. *Frontiers in Oncology*, 9. DOI: <https://doi.org/10.3389/fonc.2019.01215>
- Vannini, I., Fanini, F., & Fabbri, M. (2018). Emerging roles of microRNAs in cancer. *Current Opinion in Genetics and Development*, 48, 128–133. DOI: <https://doi.org/10.1016/j.gde.2018.01.001>
- Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., Mruthyunjaya, P., & Mahajan, V. B. (2021). Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. *Molecular Cancer*, 20(1). DOI: <https://doi.org/10.1186/s12943-021-01336-4>
- Veryaskina, Y. A., Titov, S. E., & Zhimulev, I. F. (2022). Reference genes for qPCR-based miRNA expression profiling in 14 human tissues. *Medical Principles and Practice*, 31(4), 322–332. DOI: <https://doi.org/10.1159/000524283>
- Vitto, V. A. M., Bianchin, S., Zolondick, A. A., Pelliello, G., Rimessi, A., Chianese, D., Yang, H., Carbone, M., Pinton, P., Giorgi, C., & Patergnani, S. (2022). Molecular mechanisms of autophagy in cancer development, progression, and therapy. *Biomedicines*, 10 (7). DOI: <https://doi.org/10.3390/biomedicines10071596>
- Voigt, E., Wallenburg, M., Wollenzien, H., Thompson, E., Kumar, K., Feiner, J., McNally, M., Friesen, H., Mukherjee, M., Afeworki, Y., & Kareta, M. S. (2021). Sox2 is an oncogenic driver of small-cell lung cancer and promotes the classic neuroendocrine subtype. *Molecular Cancer Research*, 19(12), 2015–2025. DOI: <https://doi.org/10.1158/1541-7786.MCR-20-1006>
- Wadowska, K., Bil-Lula, I., Trembecki, Ł., & Śliwińska-Mossoń, M. (2020). Genetic markers in lung cancer diagnosis: a review. *International Journal of Molecular Sciences*, 21(13), 1–24. DOI: <https://doi.org/10.3390/ijms21134569>
- Walsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L., & Kolb, H. C. (2014). The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. *Antioxidants and Redox Signaling*, 21(10), 1516–1554. DOI: <https://doi.org/10.1089/ars.2013.5378>
- Walter, R. F. H., Vollbrecht, C., Werner, R., Wohlschlaeger, J., Christoph, D. C., Schmid, K. W., & Mairinger, F. D. (2016). MicroRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. *Oncotarget*, 7(14), 18713–18721. DOI: <https://doi.org/10.18632/oncotarget.7666>
- Wan, L., Zhang, L., Fan, K., & Wang, J. (2014). MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. *Molecular and Cellular Biochemistry*, 390 (1–2), 85–91. DOI: <https://doi.org/10.1007/s11010-013-1959-1>
- Wang, B., Kohli, J., & Demaria, M. (2020). Senescent cells in cancer therapy: friends or foes?. *Trends in Cancer*, 6(10), 838–857. DOI: <https://doi.org/10.1016/j.trecan.2020.05.004>
- Wang, B., Liu, X., Liu, H., Guo, J., Zhang, T., Zhou, N., Ma, Y., Yu, H., Chen, L., Ren, Z., Fan, K., & Tian, X. (2018). Differential expressions of MDM2 and TAP73 in cancer and cancer-adjacent tissues in patients with non-small-cell lung carcinoma. *Revista Portuguesa de Pneumologia*, 24(3), 155–163. DOI: <https://doi.org/10.1016/j.rppnen.2017.08.008>

- Wang, H., Horbinski, C., Wu, H., Liu, Y., Sheng, S., Liu, J., Weiss, H., Stromberg, A. J., & Wang, C. (2016). NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. *Nucleic Acids Research*, 44(20), e151. DOI: <https://doi.org/10.1093/nar/gkw677>
- Wang, J., Shi, C., Wang, J., Cao, L. I., Zhong, L. I., & Wang, D. (2017). MicroRNA-320a is downregulated in non-small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin-like growth factor 1 receptor. *Oncology Letters*, 13(5), 3247–3252. DOI: <https://doi.org/10.3892/ol.2017.5863>
- Wang, J., Zhou, F., Yin, L., Zhao, L., Zhang, Y., & Wang, J. (2017). MicroRNA-199b targets the regulation of ZEB1 expression to inhibit cell proliferation, migration and invasion in non-small cell lung cancer. *Molecular Medicine Reports*, 16(4), 5007–5014. DOI: <https://doi.org/10.3892/mmr.2017.7195>
- Wang, L. H., Wu, C. F., Rajasekaran, N., & Shin, Y. K. (2019). Loss of tumor suppressor gene function in human cancer: an overview. *Cellular Physiology and Biochemistry*, 51(6), 2647–2693. DOI: <https://doi.org/10.1159/000495956>
- Wang, N., Zhu, C., Xu, Y., Qian, W., & Zheng, M. (2018). Negative Regulation of PTEN by microRNA-221 and its association with drug resistance and cellular senescence in lung cancer cells. *BioMed Research International*. DOI: <https://doi.org/10.1155/2018/7908950>
- Wang, P., Yang, D., Zhang, H., Wei, X., Ma, T., Cheng, Z., Hong, Q., Hu, J., Zhuo, H., Song, Y., Jia, C., Jing, F., Jin, Q., Bai, C., Mao, H., & Zhao, J. (2015). Early detection of lung cancer in serum by a panel of microRNA biomarkers. *Clinical Lung Cancer*, 16(4), 313-319. DOI: <https://doi.org/10.1016/j.clcc.2014.12.006>
- Wang, R., Li, G., Zhuang, G., Sun, S., & Song, Z. (2019). Overexpression of microRNA-423-3p indicates poor prognosis and promotes cell proliferation, migration, and invasion of lung cancer. *Diagnostic Pathology*, 14(1). DOI: <https://doi.org/10.1186/s13000-019-0831-3>
- Wang, S., Li, Z., Li, P., Li, L., Liu, Y., Feng, Y., Li, R., & Xia, S. (2023). SOX2 promotes radioresistance in non-small cell lung cancer by regulating tumor cells dedifferentiation. *International Journal of Medical Sciences*, 20(6), 781–796. DOI: <https://doi.org/10.7150/ijms.75315>
- Wang, S., & Zhang, Y. (2020). HMGB1 in inflammation and cancer. *Journal of Hematology and Oncology*, 13(1). DOI: <https://doi.org/10.1186/s13045-020-00950-x>
- Wang, X., Tian, L., Lu, J., & Ng, I. O. L. (2022). Exosomes and cancer - diagnostic and prognostic biomarkers and therapeutic vehicle. *Oncogenesis*, 11(1). DOI: <https://doi.org/10.1038/s41389-022-00431-5>
- Wang, X., Zhi, X., Zhang, Y., An, G., & Feng, G. (2016). Role of plasma microRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study. *Journal of Thoracic Disease*, 8(7), 1645–1652. DOI: <https://doi.org/10.21037/jtd.2016.06.21>
- Watabe-Uchida, M., Govek, E. E., & Van Aelst, L. (2006). Regulators of Rho GTPases in neuronal development. *Journal of Neuroscience*, 26(42), 10633–10635. DOI: <https://doi.org/10.1523/JNEUROSCI.4084-06.2006>
- Wei, H., Chen, Q., Lin, L., Sha, C., Li, T., Liu, Y., Yin, X., Xu, Y., Chen, L., Gao, W., Li, Y., & Zhu, X. (2020). Regulation of exosome production and cargo sorting.

- International Journal of Biological Sciences*, 17(1), 163–177. DOI: <https://doi.org/10.7150/ijbs.53671>
- Wei Zhou, C., Jun Zhao, W., Gang Zhu, Y., & Dong Zhao, X. (2018). MiR-185 inhibits tumor growth and enhances chemo-resistance via targeting SRY-related high mobility group box transcription factor 13 in non-small-cell carcinoma. *Am J Transl Res*, 10(8), 2600-2609.
- Weichert, W., & Warth, A. (2014). Early lung cancer with lepidic pattern: Adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. *Current Opinion in Pulmonary Medicine*, 20(4), 309–316. DOI: <https://doi.org/10.1097/MCP.0000000000000065>
- Wen, W., Goh, B., Lee, Y. H., Ramdzan, Z. M., Chung, M. C. M., Wong, L., & Sergot, M. J. (2011). A network-based maximum link approach towards MS identifies potentially important roles for undetected ARRB1/2 and ACTB in liver cancer progression. *J. Bioinformatics Research and Applications*.
- Wong, R. S. Y. (2011). Apoptosis in cancer: from pathogenesis to treatment. *Journal of Experimental and Clinical Cancer Research*, 30(1). DOI: <https://doi.org/10.1186/1756-9966-30-87>
- Wortzel, I., Dror, S., Kenific, C. M., & Lyden, D. (2019). Exosome-mediated metastasis: communication from a distance. *Developmental Cell*, 49(3), 347–360. DOI: <https://doi.org/10.1016/j.devcel.2019.04.011>
- Wu, B., Wang, Q., Shi, X., & Jiang, M. (2022). Targeting endocytosis and cell communications in the tumor immune microenvironment. *Cell Communication and Signaling*, 20(1). DOI: <https://doi.org/10.1186/s12964-022-00968-3>
- Wu, D. W., Cheng, Y. W., Wang, J., Chen, C. Y., & Lee, H. (2010). Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. *Cancer Research*, 70(24), 10392–10401. DOI: <https://doi.org/10.1158/0008-5472.CAN-10-2341>
- Wu, J., Lu, X., & Yan, C. (2025). Neuro-immune-cancer interactions: mechanisms and therapeutic implications for tumor modulation. *Brain Behavior and Immunity Integrative*, 10, 100119. DOI: <https://doi.org/10.1016/j.bbii.2025.100119>
- Wu, J., & Shen, Z. (2020). Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer. *Cancer Medicine*, 9(19), 6909–6922. DOI: <https://doi.org/10.1002/cam4.3379>
- Wu, K., He, J., Pu, W., & Peng, Y. (2018). The role of exportin-5 in microRNA biogenesis and cancer. *Genomics, Proteomics and Bioinformatics*, 16(2), 120–126. DOI: <https://doi.org/10.1016/j.gpb.2017.09.004>
- Wu, S. G., Chang, T. H., Liu, Y. N., & Shih, J. Y. (2019). MicroRNA in lung cancer metastasis. *Cancers*, 11(2). DOI: <https://doi.org/10.3390/cancers11020265>
- Wu, Y., Hong, Q., Lu, F., Zhang, Z., Li, J., Nie, Z., & He, B. (2023). The diagnostic and prognostic value of miR-155 in cancers: an updated meta-analysis. *Molecular Diagnosis and Therapy*, 27(3), 283–301. DOI: <https://doi.org/10.1007/s40291-023-00641-6>
- Xia, Z., Qing, B., Wang, W., Gu, L., Chen, H., & Yuan, Y. (2021). Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics. *Thoracic Cancer*, 12(23), 3088–3100. DOI: <https://doi.org/10.1111/1759-7714.14217>

- Xiao, X. H., Lv, L. C., Duan, J., Wu, Y. M., He, S. J., Hu, Z. Z., & Xiong, L. X. (2018). Regulating Cdc42 and its signaling pathways in cancer: small molecules and microRNA as new treatment candidates. *Molecules*, 23(4). DOI: <https://doi.org/10.3390/molecules23040787>
- Xu, C., Li, H., Zhang, L., Jia, T., Duan, L., & Lu, C. (2016). MicroRNA-1915-3p prevents the apoptosis of lung cancer cells by downregulating DRG2 and PBX2. *Molecular Medicine Reports*, 13(1), 505–512. DOI: <https://doi.org/10.3892/mmr.2015.4565>
- Xu, D. W., Zhang, G. Q., Wang, Z. W., Xu, X. Y., & Liu, T. X. (2015). Autophagy in tumorigenesis and cancer treatment. *Asian Pacific Journal of Cancer Prevention*, 16(6), 2167–2175. DOI: <https://doi.org/10.7314/APJCP.2015.16.6.2167>
- Xu, L., Li, M., Wang, M., Yan, D., Feng, G., & An, G. (2014). The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. *BMC Cancer*, 14(1). DOI: <https://doi.org/10.1186/1471-2407-14-714>
- Xu, W., Liu, D., Yang, Y., Ding, X., Sun, Y., Zhang, B., Xu, J., & Su, B. (2016). Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women. *Journal of Thoracic Disease*, 8(9), 2519–2529. DOI: <https://doi.org/10.21037/jtd.2016.08.70>
- Xu, Y., Yao, Y., Yu, L., Fung, H. L., Tang, A. H. N., Ng, I. O. L., Wong, M. Y. M., Che, C. M., Yun, J. P., Cui, Y., & Yam, J. W. P. (2023). Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression. *Hepatology International*, 17(6), 1490–1499. DOI: <https://doi.org/10.1007/s12072-023-10562-5>
- Xu, Y., Zhang, Q., Lin, F., Zhu, L., Huang, F., Zhao, L., & Ou, R. (2019). Casiopeina II-gly acts on lncRNA MALAT1 by miR-17-5p to inhibit FZD2 expression via the Wnt signaling pathway during the treatment of cervical carcinoma. *Oncology Reports*, 42(4), 1365–1379. DOI: <https://doi.org/10.3892/or.2019.7268>
- Xue, X., Wang, C., Xue, Z., Wen, J., Han, J., Ma, X., Zang, X., Deng, H., Guo, R., Asuquo, I. P., Qin, C., Wang, H., Gao, Q., Liu, S., & Wang, J. (2020). Exosomal miRNA profiling before and after surgery revealed potential diagnostic and prognostic markers for lung adenocarcinoma. *Acta Biochimica et Biophysica Sinica*, 52(3), 281–293. DOI: <https://doi.org/10.1093/ABBS/GMZ164>
- Yakubovich, E. I., Polischouk, A. G., & Evtushenko, V. I. (2022). Principles and problems of exosome isolation from biological fluids. *Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology*, 16(2), 115–126. DOI: <https://doi.org/10.1134/S1990747822030096>
- Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008). MiR-34a repression of SIRT1 regulates apoptosis. *PNAS*, 105(36), 13421–13426.
- Yamamoto, K., & Chiba, M. (2024). Examination and comparison of the RNA extraction methods using mouse serum. *Biomedical Reports*, 20(3), 1–7. DOI: <https://doi.org/10.3892/br.2024.1739>
- Yan, H. J., Ma, J. Y., Wang, L., & Gu, W. (2015). Expression and significance of circulating microRNA-31 in lung cancer patients. *Medical Science Monitor*, 21, 722–726. DOI: <https://doi.org/10.12659/MSM.893213>

- Yan, J., Liu, T., Zhou, X., Dang, Y., Yin, C., & Zhang, G. (2016). FZD6, targeted by miR-21, represses gastric cancer cell proliferation and migration via activating non-canonical wnt pathway. *Am J Transl Res*, 8(5), 2354-2364.
- Yan, L., Jiao, D., Hu, H., Wang, J., Tang, X., Chen, J., & Chen, Q. (2017). Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach. *Experimental Biology and Medicine*, 242(7), 709-717. DOI: <https://doi.org/10.1177/1535370216677353>
- Yan, L., Tan, Y., Chen, G., Fan, J., & Zhang, J. (2021). Harnessing metabolic reprogramming to improve cancer immunotherapy. *International Journal of Molecular Sciences*, 22(19). DOI: <https://doi.org/10.3390/ijms221910268>
- Yan, W., Wu, X., Zhou, W., Fong, M. Y., Cao, M., Liu, J., Liu, X., Chen, C. H., Fadare, O., Pizzo, D. P., Wu, J., Liu, L., Liu, X., Chin, A. R., Ren, X., Chen, Y., Locasale, J. W., & Wang, S. E. (2018). Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. *Nature Cell Biology*, 20(5), 597-609. DOI: <https://doi.org/10.1038/s41556-018-0083-6>
- Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., Calin, G. A., Liu, C., Croce, C. M., & Harris, C. C. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell*, 9, 189-198. DOI: <https://doi.org/10.1016/j.ccr.2006.01.025>
- Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021). The paradoxical role of cellular senescence in cancer. *Frontiers in Cell and Developmental Biology*, 9. DOI: <https://doi.org/10.3389/fcell.2021.722205>
- Yang, P., Song, F., Yang, X., Yan, X., Huang, X., Qiu, Z., Wen, Z., Liang, C., Xin, X., Lei, Z., Zhang, K., Yang, J., Liu, H., Wang, H., Xiang, S., Li, L., Zhang, B., & Wang, H. (2022). Exosomal microRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma. *IScience*, 25(9). DOI: <https://doi.org/10.1016/j.isci.2022.104816>
- Yang, X., Liang, X., Zheng, M., & Tang, Y. (2018). Cellular phenotype plasticity in cancer dormancy and metastasis. *Frontiers in Oncology*, 8. DOI: <https://doi.org/10.3389/fonc.2018.00505>
- Yang, X., Zheng, F., Zhang, S., & Lu, J. (2015). Loss of RhoA expression prevents proliferation and metastasis of SPCA1 lung cancer cells in vitro. *Biomedicine and Pharmacotherapy*, 69, 361-366. DOI: <https://doi.org/10.1016/j.biopha.2014.12.004>
- Yang, Y., Hu, Z., Zhou, Y., Zhao, G., Lei, Y., Li, G., Chen, S., Chen, K., Shen, Z., Chen, X., Dai, P., & Huang, Y. (2017). The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers. *Oncotarget*, 8(52), 90197-90214. www.impactjournals.com/oncotarget
- Yang, Y., Zhang, M., & Wang, Y. (2022). The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. *Journal of the National Cancer Center*, 2(4), 277-290. DOI: <https://doi.org/10.1016/j.jncc.2022.09.002>

- Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011). The role of autophagy in cancer: therapeutic implications. *Molecular Cancer Therapeutics*, 10(9), 1533–1541. DOI: <https://doi.org/10.1158/1535-7163.MCT-11-0047>
- Yao, Q., Chen, Y., & Zhou, X. (2019). The roles of microRNAs in epigenetic regulation. *Current Opinion in Chemical Biology*, 51, 11–17. DOI: <https://doi.org/10.1016/j.cbpa.2019.01.024>
- Ye, J., Xu, M., Tian, X., Cai, S., & Zeng, S. (2019). Research advances in the detection of miRNA. *Journal of Pharmaceutical Analysis*, 9(4), 217–226. DOI: <https://doi.org/10.1016/j.jpha.2019.05.004>
- Yip, R., Yankelevitz, D. F., Hu, M., Li, K., Xu, D. M., Jirapatnakul, A., & Henschke, C. I. (2016). Lung cancer deaths in the national lung screening trial attributed to nonsolid nodules. *Radiology*, 281(2), 589–596. DOI: <https://doi.org/10.1148/radiol.2016152333>
- Yu, J., Wang, J.-G., Zhang, L., Yang, H.-P., Wang, L., Ding, D., Chen, Q., Yang, W.-L., Ren, K.-H., Zhou, D.-M., Zou, Q., Jin, Y.-T., & Liu, X.-P. (2016). MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin. *Oncotarget*, 7(25), 38612–38625.
- Yu, W., Hurley, J., Roberts, D., Chakraborty, S. K., Enderle, D., Noerholm, M., Breakefield, X. O., & Skog, J. K. (2021). Exosome-based liquid biopsies in cancer: opportunities and challenges. *Annals of Oncology*, 32(4), 466–477. DOI: <https://doi.org/10.1016/j.annonc.2021.01.074>
- Yue, B., Yang, H., Wang, J., Ru, W., Wu, J., Huang, Y., Lan, X., Lei, C., & Chen, H. (2020). Exosome biogenesis, secretion and function of exosomal miRNAs in skeletal muscle myogenesis. *Cell Proliferation*, 53(7). DOI: <https://doi.org/10.1111/cpr.12857>
- Zafar, A., Khan, M. J., & Naeem, A. (2023). MDM2- an indispensable player in tumorigenesis. *Molecular Biology Reports*, 50(8), 6871–6883. DOI: <https://doi.org/10.1007/s11033-023-08512-3>
- Zedan, A. H., Hansen, T. F., Assenholt, J., Pleckaitis, M., Madsen, J. S., & Osther, P. J. S. (2018). MicroRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer. *Tumor Biology*, 40(5). DOI: <https://doi.org/10.1177/1010428318775864>
- Zeng, C. M., Chen, Z., & Fu, L. (2018). Frizzled receptors as potential therapeutic targets in human cancers. *International Journal of Molecular Sciences*, 19(5). DOI: <https://doi.org/10.3390/ijms19051543>
- Zeng, Z., Li, Y., Pan, Y., Lan, X., Song, F., Sun, J., Zhou, K., Liu, X., Ren, X., Wang, F., Hu, J., Zhu, X., Yang, W., Liao, W., Li, G., Ding, Y., & Liang, L. (2018). Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. *Nature Communications*, 9(1). DOI: <https://doi.org/10.1038/s41467-018-07810-w>
- Zer, A., Ahn, M.-J., Barlesi, F., Bubendorf, L., De Ruyscher, D., Garrido, P., Gautschi, O., Hendriks, L. E., Jänne, P. A., Kerr, K. M., Mascaux, C., Mitsudomi, T., Peters, S., Rolfo, C., Sacher, A., Senan, S., Ugalde, P., & Leighl, N. B. (2025). Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*, 36(11), 1245–1262. DOI: <https://doi.org/10.1016/j.annonc.2025.08.003>

- Zhai, C., Liu, B., Kan, F., Zhai, S., & Zhang, R. (2023). MicroRNA-27a-3p regulates the proliferation and chemotaxis of pulmonary macrophages in non-small cell lung carcinoma tissues through CXCL2. *Oncology Letters*, 26(5). DOI: <https://doi.org/10.3892/ol.2023.14079>
- Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007). microRNAs as oncogenes and tumor suppressors. *Developmental Biology*, 302(1), 1–12. DOI: <https://doi.org/10.1016/j.ydbio.2006.08.028>
- Zhang, G., Jiang, G., Wang, C., Zhong, K., Zhang, J., Xue, Q., Li, X., Jin, H., & Li, B. (2016). Decreased expression of microRNA-320a promotes proliferation and invasion of non-small cell lung cancer cells by increasing VDAC1 expression. *Oncotarget*, 7(3), 49470–49480.
- Zhang, J., Cheng, J., Zeng, Z., Wang, Y., Li, X., Xie, Q., Jia, J., Yan, Y., Guo, Z., Gao, J., Yao, M., Chen, X., & Lu, F. (2015). Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. *Oncotarget*, 6(39), 42040–42052. DOI: <https://doi.org/10.18632/oncotarget.5969>
- Zhang, L., Chen, H., He, F., Zhang, S., Li, A., Zhang, A., & Zhang, A. (2021). MicroRNA-320a promotes epithelial ovarian cancer cell proliferation and invasion by targeting RASSF8. *Frontiers in Oncology*, 11. DOI: <https://doi.org/10.3389/fonc.2021.581932>
- Zhang, L., Liang, Y., Li, S., Zeng, F., Meng, Y., Chen, Z., Liu, S., Tao, Y., & Yu, F. (2019). The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. *Molecular Cancer*, 18(1). DOI: <https://doi.org/10.1186/s12943-019-0989-z>
- Zhang, Q., Chen, Y., & Liu, K. (2018). MiR-185 inhibits cell migration and invasion of hepatocellular carcinoma through CDC42. *Oncology Letters*, 16(3), 3101–3107. DOI: <https://doi.org/10.3892/ol.2018.8971>
- Zhang, Q., Zhu, B., & Li, Y. (2017). Resolution of cancer-promoting inflammation: a new approach for anticancer therapy. *Frontiers in Immunology*, 8. DOI: <https://doi.org/10.3389/fimmu.2017.00071>
- Zhang, S. S., Nagasaka, M., Zhu, V. W., & Ou, S. H. I. (2021). Going beneath the tip of the iceberg. identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. *Lung Cancer*, 158, 126–136. DOI: <https://doi.org/10.1016/j.lungcan.2021.06.012>
- Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024). Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. *Signal Transduction and Targeted Therapy*, 9(1). DOI: <https://doi.org/10.1038/s41392-024-01848-7>
- Zhang, W., Ni, M., Su, Y., Wang, H., Zhu, S., Zhao, A., & Li, G. (2018). MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. *European Urology Focus*, 4(3), 412–419. DOI: <https://doi.org/10.1016/j.euf.2016.09.007>
- Zhang, Y., Bi, J., Huang, J., Tang, Y., Du, S., & Li, P. (2020). Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. *International Journal of Nanomedicine*, 15, 6917–6934. DOI: <https://doi.org/10.2147/IJN.S264498>

- Zhang, Z., Li, X., Sun, W., Yue, S., Yang, J., Li, J., Ma, B., Wang, J., Yang, X., Pu, M., Ruan, B., Zhao, G., Huang, Q., Wang, L., Tao, K., & Dou, K. (2017). Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. *Cancer Letters*, 397, 33–42. DOI: <https://doi.org/10.1016/j.canlet.2017.03.004>
- Zhao, H., Wu, X., Wang, Y., Li, X., Du, Y., Zhou, Z., Li, Y., Liu, Y., Zeng, X., & Chen, G. (2024). Histone variant H2AZ1 drives lung cancer progression through the RELA-HIF1A-EGFR signaling pathway. *Cell Communication and Signaling*, 22(1). DOI: <https://doi.org/10.1186/s12964-024-01823-3>
- Zhao, J., & Jin, J. (2022). Neutrophil extracellular traps: new players in cancer research. *Frontiers in Immunology*, 13. DOI: <https://doi.org/10.3389/fimmu.2022.937565>
- Zhao, K., Cheng, J., Chen, B., Liu, Q., Xu, D., & Zhang, Y. (2017). Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer. *Journal of Thoracic Disease*, 9(10), 3735–3746. DOI: <https://doi.org/10.21037/jtd.2017.09.01>
- Zhao, L., Wang, Y., & Jiang, C. (2018). MicroRNA-18b promotes cell proliferation and invasion in non-small cell lung cancer by directly targeting runt-related transcription factor 3. *Biomedical Research*, 29(1), 71–77. DOI: <https://doi.org/10.4066/biomedicalresearch.29-17-1966>
- Zhao, L., Zhou, Y., Zhao, Y., Li, Q., Zhou, J., & Mao, Y. (2020). Long non-coding RNA TUSC8 inhibits breast cancer growth and metastasis via miR-190b-5p/MYLIP axis. *Anging 2020*, 12(3), 2974–2991.
- Zhao, Q., Liu, C., Cui, Q., Luan, X., Wang, Q., & Zhou, C. (2019). miR-190b promotes colorectal cancer progression through targeting forkhead box protein P2. *Experimental and Therapeutic Medicine*, 19, 79-84. DOI: <https://doi.org/10.3892/etm.2019.8175>
- Zhao, S., Wang, Y., Lou, Y., Wang, Y., Sun, J., Luo, M., Li, W., & Miao, L. (2018). MicroRNA-320a suppresses tumour cell proliferation and invasion of renal cancer cells by targeting FoxM1. *Oncology Reports*, 40(4), 1917–1926. DOI: <https://doi.org/10.3892/or.2018.6597>
- Zheng, C., Wang, Y., Yang, L., Zhou, S., Gao, Y., Li, F., Feng, Y., Wang, Z., Zhan, L., Yan, Q., Zhu, X., Wong, K. K., Chen, Z., & Ji, H. (2017). Cell division cycle 42 plays a cell type-specific role in lung tumorigenesis. *Scientific Reports*, 7(1). DOI: <https://doi.org/10.1038/s41598-017-10891-0>
- Zheng, M. (2016). Classification and Pathology of Lung Cancer. *Surgical Oncology Clinics of North America*, 25(3), 447–468. DOI: <https://doi.org/10.1016/j.soc.2016.02.003>
- Zhou, G., Xie, J., Gao, Z., & Yao, W. (2019). MicroRNA-877 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting IGF-1R. *Experimental and Therapeutic Medicine*, 18(2), 1449-1457. DOI: <https://doi.org/10.3892/etm.2019.7676>
- Zhou, H., Liu, Y., Xiao, L., Hu, Z., & Xia, K. (2017). Overexpression of MicroRNA-27b inhibits proliferation, migration, and invasion via suppression of MET expression. *Oncology Research*, 25(1), 147–154. DOI: <https://doi.org/10.3727/096504016X14732772150505>



- Zhou, M., Weber, S. R., Zhao, Y., Chen, H., & Sundstrom, J. M. (2019). Methods for exosome isolation and characterization. *Exosomes: A Clinical Compendium*, 23–38. DOI: <https://doi.org/10.1016/B978-0-12-816053-4.00002-X>
- Zhou, R., Zhou, X., Yin, Z., Guo, J., Hu, T., Jiang, S., Liu, L., Dong, X., Zhang, S., & Wu, G. (2016). MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU. *Scientific Reports*, 6. DOI: <https://doi.org/10.1038/srep35714>
- Zhu, C., Kong, Z., Wang, B., Cheng, W., Wu, A., & Meng, X. (2019). Review Article ITGB3/CD61: a hub modulator and target in the tumor microenvironment. *Am J Transl Res*, 11 (12).
- Zhu, C. Q., Popova, S. N., Brown, E. R. S., Barsyte-Lovejoy, D., Navab, R., Shih, W., Li, M., Lu, M., Jurisica, I., Penn, L. Z., Gullberg, D., & Tsao, M. S. (2007). Integrin $\alpha 11$ regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, 104(28), 11754–11759. DOI: <https://doi.org/10.1073/pnas.0703040104>
- Zhu, J., Wang, M., & Hu, D. (2020). Development of an autophagy-related gene prognostic signature in lung adenocarcinoma and lung squamous cell carcinoma. *PeerJ*, 1. DOI: <https://doi.org/10.7717/peerj.8288>
- Zhu, Y., Li, T., Chen, G., Yan, G., Zhang, X., Wan, Y., Li, Q., Zhu, B., & Zhuo, W. (2017). Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p. *Lung Cancer*, 114, 6–11. DOI: <https://doi.org/10.1016/j.lungcan.2017.10.002>
- Zocco, D., Bernardi, S., Novelli, M., Astrua, C., Fava, P., Zarovni, N., Carpi, F. M., Bianciardi, L., Malavenda, O., Quaglino, P., Foroni, C., Russo, D., Chiesi, A., & Fierro, M. T. (2020). Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. *Scientific Reports*, 10(1), 1–12. DOI: <https://doi.org/10.1038/s41598-020-72834-6>
- Zou, Y., Jing, C., Liu, L., & Wang, T. (2019). Serum microRNA-135 a as a diagnostic biomarker in non-small cell lung cancer. *Medicine (United States)*, 98(50). DOI: <https://doi.org/10.1097/MD.00000000000017814>.